10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2011

OR

[   ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from            to            

Commission File Number 001-15103

INVACARE CORPORATION

(Exact name of registrant as specified in its charter)

Ohio	95-2680965
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No)
One Invacare Way, P.O. Box 4028, Elyria, Ohio	44036
(Address of principal executive offices)	(Zip Code)

(440) 329-6000

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 (the “Exchange Act”) during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  X    No      

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes  X    No      

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “small reporting company” in Rule 12b-2 of the Exchange Act. (Check One):    Large accelerated filer          Accelerated filer    X      Non-accelerated filer        (Do not check if a smaller reporting company) Smaller reporting company      

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes        No    X  

As of August 2, 2011, the registrant had 30,872,004 Common Shares and 1,084,747 Class B Common Shares outstanding.

INVACARE CORPORATION

INDEX

Part I. FINANCIAL INFORMATION:	Page No.
Item 1. Financial Statements (Unaudited)
Condensed Consolidated Balance Sheets – June 30, 2011 and December 31, 2010	3
Condensed Consolidated Statement of Earnings – Three and Six Months Ended June 30, 2011 and June 30, 2010	4
Condensed Consolidated Statement of Cash Flows – Six Months Ended June 30, 2011 and June 30, 2010	5
Notes to Condensed Consolidated Financial Statements – June 30, 2011	6
Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations	26
Item 3. Quantitative and Qualitative Disclosures About Market Risk	35
Item 4. Controls and Procedures	35
Part II. OTHER INFORMATION:
Item 1. Legal Proceedings	36
Item 1A. Risk Factors	36
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	36
Item 6. Exhibits	36
SIGNATURES	37

2

Part I.	FINANCIAL INFORMATION
Item 1.	Financial Statements.

INVACARE CORPORATION AND SUBSIDIARIES

Condensed Consolidated Balance Sheets (unaudited)

	June 30, 2011			December 31, 2010
ASSETS	(In thousands)
CURRENT ASSETS
Cash and cash equivalents	$	38,162		$	48,462
Trade receivables, net		268,753			252,004
Installment receivables, net		5,977			3,959
Inventories, net		188,812			174,375
Deferred income taxes		6,020			5,778
Other current assets		49,534			41,581
TOTAL CURRENT ASSETS		557,258			526,159
OTHER ASSETS		45,173			45,484
OTHER INTANGIBLES		72,271			70,911
PROPERTY AND EQUIPMENT, NET		134,037			130,763
GOODWILL		553,504			507,083
TOTAL ASSETS	$	1,362,243		$	1,280,400
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES
Accounts payable	$	160,622		$	143,753
Accrued expenses		134,288			130,079
Accrued income taxes		1,405			8,502
Short-term debt and current maturities of long-term obligations		8,431			7,974
TOTAL CURRENT LIABILITIES		304,746			290,308
LONG-TERM DEBT		247,297			238,090
OTHER LONG-TERM OBLIGATIONS		107,255			99,591
SHAREHOLDERS’ EQUITY
Preferred shares		0			0
Common shares		8,445			8,401
Class B common shares		272			272
Additional paid-in-capital		221,821			231,685
Retained earnings		387,322			370,001
Accumulated other comprehensive earnings		171,905			112,631
Treasury shares		(86,820	)		(70,579	)
TOTAL SHAREHOLDERS’ EQUITY		702,945			652,411
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	1,362,243		$	1,280,400

See notes to condensed consolidated financial statements.

3

INVACARE CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statement of Earnings - (unaudited)

	Three Months Ended   June 30,						Six Months Ended   June 30,
(In thousands except per share data)	2011			2010			2011			2010
Net sales	$	466,412		$	430,828		$	894,910		$	833,068
Cost of products sold		331,494			304,338			636,986			588,865
Gross profit		134,918			126,490			257,924			244,203
Selling, general and administrative expense		112,417			104,421			218,194			206,197
Loss on debt extinguishment including debt finance charges and associated fees		11,855			14,048			16,736			18,434
Charge related to restructuring activities		431			0			431			0
Interest expense		2,233			5,770			4,844			12,162
Interest income		(279	)		(163	)		(546	)		(310	)
Earnings before income taxes		8,261			2,414			18,265			7,720
Income taxes (benefit)		(2,400	)		3,025			150			5,225
NET EARNINGS (LOSS)	$	10,661		$	(611	)	$	18,115		$	2,495
DIVIDENDS DECLARED PER COMMON SHARE		.0125			.0125			.0250			.0250
Net earnings (loss) per share – basic	$	0.33		$	(0.02	)	$	0.56		$	0.08
Weighted average shares outstanding - basic		31,950			32,386			32,062			32,367
Net earnings (loss) per share – assuming dilution	$	0.32		$	(0.02	)	$	0.55		$	0.08
Weighted average shares outstanding - assuming dilution		33,006			32,386			33,026			32,669

See notes to condensed consolidated financial statements.

4

INVACARE CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statement of Cash Flows - (unaudited)

	Six Months Ended June 30,
	2011			2010
OPERATING ACTIVITIES	(In thousands)
Net earnings	$	18,115		$	2,495
Adjustments to reconcile net earnings to net cash provided by operating activities:
Amortization of convertible debt discount		1,136			1,706
Loss on debt extinguishment including debt finance charges and associated fees		16,736			18,434
Depreciation and amortization		18,133			18,245
Provision for losses on trade and installment receivables		7,360			8,112
Provision for other deferred liabilities		1,508			1,421
Provision (benefit) for deferred income taxes		(628	)		(117	)
Provision for stock-based compensation		2,878			2,840
Gain (loss) on disposals of property and equipment		151			9
Changes in operating assets and liabilities:
Trade receivables		(15,359	)		(5,132	)
Installment sales contracts, net		(2,344	)		(466	)
Inventories		(6,921	)		(9,807	)
Other current assets		(4,855	)		6,916
Accounts payable		12,356			13,780
Accrued expenses		(12,942	)		(6,499	)
Other deferred liabilities		1,672			2,143
NET CASH PROVIDED BY OPERATING ACTIVITIES		36,996			54,080
INVESTING ACTIVITIES
Purchases of property and equipment		(10,104	)		(8,422	)
Proceeds from sale of property and equipment		37			313
Other long term assets		(1,011	)		813
Business acquisitions, net of cash acquired		0			(13,725	)
Other		(76	)		(223	)
NET CASH USED FOR INVESTING ACTIVITIES		(11,154	)		(21,244	)
FINANCING ACTIVITIES
Proceeds from revolving lines of credit and long-term borrowings		230,752			201,661
Payments on revolving lines of credit and long-term debt and capital lease obligations		(237,881	)		(219,847	)
Proceeds from exercise of stock options		4,101			1,002
Payment of financing costs		(18,116	)		(16,549	)
Payment of dividends		(794	)		(808	)
Purchase of treasury stock		(16,213	)		0
NET CASH USED BY FINANCING ACTIVITIES		(38,151	)		(34,541	)
Effect of exchange rate changes on cash		2,009			(4,591	)
Decrease in cash and cash equivalents		(10,300	)		(6,296	)
Cash and cash equivalents at beginning of period		48,462			37,501
Cash and cash equivalents at end of period	$	38,162		$	31,205

See notes to condensed consolidated financial statements.

5

INVACARE CORPORATION AND SUBSIDIARIES

Notes to Condensed Consolidated

Financial Statements

(Unaudited)

June 30, 2011

Nature of Operations - Invacare Corporation is the world’s leading manufacturer and distributor in the estimated $11.0 billion worldwide market for medical equipment and supplies used in the home based upon the Company’s distribution channels, breadth of product line and net sales. The Company designs, manufactures and distributes an extensive line of health care products for the non-acute care environment, including the home health care, retail and extended care markets.

Principles of Consolidation - The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and include all adjustments, which were of a normal recurring nature, necessary to present fairly the financial position of the Company as of June 30, 2011, the results of its operations for the three and six months ended June 30, 2011 and changes in its cash flow for the six months ended June 30, 2011 and 2010, respectively. Certain foreign subsidiaries, represented by the European segment, are consolidated using a May 31 quarter end in order to meet filing deadlines. No material subsequent events have occurred related to the European segment, which would require disclosure or adjustment to the Company’s financial statements. All significant intercompany transactions are eliminated. The results of operations for the three and six months ended June 30, 2011 are not necessarily indicative of the results to be expected for the full year.

Use of Estimates - The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States, which require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates.

Accounting for Stock-Based Compensation - The Company accounts for share based compensation under the provisions of Compensation—Stock Compensation, ASC 718. The Company has not made any modifications to the terms of any previously granted options and no significant changes have been made regarding the valuation methodologies used to determine the fair value of options granted and the Company continues to use a Black-Scholes valuation model.

The substantial majority of the options awarded have been granted at exercise prices equal to the market value of the underlying stock on the date of grant. Restricted stock awards granted without cost to the recipients are expensed on a straight-line basis over the vesting periods.

The amounts of stock-based compensation expense recognized were as follows (in thousands):

	Three Months Ended June  30,				Six Months Ended June 30,
	2011		2010		2011		2010
Stock-based compensation expense recognized as part of selling, general and administrative expense	$	1,467	$	1,283	$	2,878	$	2,840

The amounts above reflect compensation expense related to restricted stock awards and nonqualified stock options awarded under the 2003 Performance Plan (the “2003 Plan”). Stock-based compensation is not allocated to the business segments, but is reported as part of All Other as shown in the Company’s Business Segment Note to the Consolidated Financial Statements.

Receivables - Accounts receivable and installment receivables are reduced by an allowance for amounts that may become uncollectible in the future. Substantially all of the Company’s receivables are due from health care, medical equipment providers and long term care facilities located throughout the United States, Australia, Canada, New Zealand and Europe. A significant portion of products sold to providers, both foreign and domestic, is ultimately funded through government reimbursement programs such as Medicare and Medicaid in the U.S. As a consequence, changes in these programs can have an adverse impact on dealer liquidity and profitability. The estimated allowance for uncollectible amounts for both trade accounts receivable and installment receivables ($30,612,000 and $30,168,000 at June 30, 2011 and December 31, 2010, respectively) is based primarily on management’s evaluation of the financial condition of specific customers. In addition, as a result of the third party financing arrangement with De Lage Landen, Inc. (DLL), a third party financing company which the Company has worked with since 2000, management monitors the collection status of these contracts in accordance with the Company’s limited recourse obligations and provides amounts necessary for estimated losses in the allowance for doubtful accounts and establishing reserves for specific customers as needed. The Company charges off uncollectible trade accounts receivable after such receivables are moved to collection status and legal remedies are exhausted. See Concentration of Credit Risk in the Notes to the Consolidated Financial Statements for a description of the financing arrangement. Long-term installment receivables are included in “Other Assets” on the consolidated balance sheet.

6

The Company’s U.S. customers electing to finance their purchases can do so using DLL. In addition, Invacare often provides financing directly for its Canadian customers for which DLL is not an option, as DLL typically provides financing to Canadian customers only on a limited basis. The installment receivables recorded on the books of the Company represent a single portfolio segment of finance receivables to the independent provider channel. The portfolio segment is comprised of two classes of receivables distinguished by geography and credit quality. The U.S. installment receivables are the first class and represent installment receivables re-purchased from DLL because the customers were in default. Default with DLL is defined as a customer being delinquent by three payments. The Canadian installment receivables represent the second class of installment receivables which were originally financed by Invacare because third party financing was not available to the HME providers. The Canadian installment receivables are typically financed for twelve months and historically have had a very low risk of default.

The estimated allowance for uncollectible amounts and evaluation for impairment for both classes of installment receivables is based on the Company’s quarterly review of the financial condition of each individual customer with the allowance for doubtful accounts adjusted accordingly. Installments are individually and not collectively reviewed for impairment. The Company assesses the bad debt reserve levels based upon the status of the customer’s adherence to a legally negotiated payment schedule and the Company’s ability to enforce judgments, liens, etc.

For purposes of granting or extending credit, the Company utilizes a scoring model to generate a composite score that considers each customer’s consumer credit score and or D&B credit rating, payment history, security collateral and time in business. Additional analysis is performed for customers desiring credit greater than $250,000 which includes a detailed review of the customer’s financials as well as consideration of other factors such as exposure to changing reimbursement laws.

Interest income is recognized on installment receivables based on the terms of the installment agreements. Installment accounts are monitored and if a customer defaults on payments and is moved to collection, interest income is no longer recognized. Subsequent payments received once an account is put on non-accrual status are generally first applied to the principal balance and then to the interest. Accruing of interest on collection accounts does not occur and accruing of interest would only be restarted if the account became current again. All installment accounts are accounted for using the same methodology regardless of the duration of the installment agreements. When an account is placed in collection status, the Company initiates a legal process of adjudication of the delinquency, the duration of which is typically approximately 18 months. Any write-offs of uncollectible amounts are made after the legal process has been completed. The Company has not made any changes to either its accounting policies or methodology to estimation allowances for doubtful accounts in the last twelve months.

Installment receivables consist of the following (in thousands):

	June 30, 2011									December 31, 2010
	Current			Long-     Term			Total			Current			Long-     Term			Total
Installment receivables	$	7,938		$	4,057		$	11,995		$	5,777		$	4,854		$	10,631
Less: Unearned interest		(192	)		0			(192	)		(118	)		0			(118	)
		7,746			4,057			11,803			5,659			4,854			10,513
Allowance for doubtful accounts		(1,769	)		(2,753	)		(4,522	)		(1,700	)		(3,141	)		(4,841	)
	$	5,977		$	1,304		$	7,281		$	3,959		$	1,713		$	5,672

Installment receivable purchased from DLL during the six months ended June 30, 2011 increased the gross installment receivables balance by $2,116,000. No sales of installment receivables were made by the Company during the year.

The movement in the installment receivables allowance for doubtful accounts was as follows (in thousands):

	Six Months Ended          June 30, 2011			Year Ended   December 31,  2010
Beginning Balance	$	4,841		$	6,080
Current period provision		857			4,022
Direct write-offs charged against the allowance		(1,176	)		(5,261	)
Ending Balance	$	4,522		$	4,841

7

Installment receivables by class as of June 30, 2011 consist of the following (in thousands):

U.S.	Total Installment Receivables		Unpaid Principal   Balance		Related Allowance for Doubtful   Accounts		Interest Income  Recognized
Impaired Installment receivables with a related allowance recorded	$	6,784	$	6,784	$	4,482	$	0
Canada
Non-Impaired Installment receivables with no related allowance recorded		5,171		4,979		0		117
Impaired Installment receivables with a related allowance recorded		40		40		40		0
Total Canadian Installment Receivables	$	5,211	$	5,019	$	40	$	117
Total
Non-Impaired Installment receivables with no related allowance recorded		5,171		4,979		0		117
Impaired Installment receivables with a related allowance recorded		6,824		6,824		4,522		0
Total Installment Receivables	$	11,995	$	11,803	$	4,522	$	117

Installment receivables by class as of December 31, 2010 consist of the following (in thousands):

U.S.	Total Installment Receivables		Unpaid Principal   Balance		Related Allowance for Doubtful   Accounts		Interest Income  Recognized
Impaired Installment receivables with a related allowance recorded	$	7,153	$	7,153	$	4,822	$	0
Canada
Non-Impaired Installment receivables with no related allowance recorded		3,222		3,104		0		109
Impaired Installment receivables with a related allowance recorded		256		256		19		0
Total Canadian Installment Receivables	$	3,478	$	3,360	$	19	$	109
Total
Non-Impaired Installment receivables with no related allowance recorded		3,222		3,104		0		109
Impaired Installment receivables with a related allowance recorded		7,409		7,409		4,841		0
Total Installment Receivables	$	10,631	$	10,513	$	4,841	$	109

Installment receivables with a related allowance recorded as noted in the table above represent those installment receivables on a non-accrual basis in accordance with ASU 2010-20. As of June 30, 2011 and December 31, 2010, the Company had no U.S. installment receivables past due of 90 days or more for which the Company is still accruing interest. Individually, all U.S. installment receivables are assigned a specific allowance for doubtful accounts based on management’s review when the Company does not expect to receive both the contractual principal and interest payments as specified in the loan agreement. However, while the full balance may be deemed to be impaired, the Company does historically collect a large percentage of the principal of its U.S. installment receivables.

The Company had an immaterial amount of Canadian installment receivables which were past due of 90 days or more as of June 30, 2011 and December 31, 2010, respectively, for which the Company is still accruing interest.

8

The aging of the Company’s installment receivables was as follows (in thousands):

	June 30, 2011						December 31, 2010
	Total		U.S.		Canada		Total		U.S.		Canada
Current	$	5,111	$	0	$	5,111	$	3,097	$	0	$	3,097
0-30 Days Past Due		44		0		44		89		0		89
31-60 Days Past Due		18		0		8		31		0		31
61-90 Days Past Due		8		0		8		5		0		5
90+ Days Past Due		6,814		6,784		40		7,409		7,153		256
	$	11,995	$	6,784	$	5,211	$	10,631	$	7,153	$	3,478

Inventories - Inventories determined under the first in, first out method consist of the following components (in thousands):

	June 30, 2011		December 31, 2010
Finished goods	$	114,857	$	101,243
Raw Materials		63,423		59,921
Work in Process		10,532		13,211
	$	188,812	$	174,375

Property and Equipment - Property and equipment consist of the following (in thousands):

	June 30, 2011			December 31, 2010
Machinery and equipment	$	351,415		$	332,687
Land, buildings and improvements		98,550			91,956
Furniture and fixtures		28,844			27,775
Leasehold improvements		16,462			15,705
		495,271			468,123
Less allowance for depreciation		(361,234	)		(337,360	)
	$	134,037		$	130,763

Goodwill and Other Intangibles - The change in goodwill reflected on the balance sheet from December 31, 2010 to June 30, 2011 was entirely the result of foreign currency translation.

All of the Company’s other intangible assets have been assigned definite lives and continue to be amortized over their useful lives, except for $33,963,000 related to trademarks, which have indefinite lives. The changes in intangible balances reflected on the balance sheet from December 31, 2010 to June 30, 2011 were the result of foreign currency translation and amortization.

As of June 30, 2011 and December 31, 2010, other intangibles consisted of the following (in thousands):

	June 30, 2011				December 31, 2010
	Historical       Cost		Accumulated       Amortization		Historical       Cost		Accumulated       Amortization
Customer lists	$	79,948	$	47,729	$	72,998	$	40,071
Trademarks		33,963		0		31,246		0
License agreements		3,243		3,015		3,183		2,958
Developed technology		9,496		4,745		8,521		3,988
Patents		6,028		5,162		7,518		5,863
Other		6,205		5,961		6,092		5,767
	$	138,883	$	66,612	$	129,558	$	58,647

Amortization expense related to other intangibles was $4,338,000 in the first six months of 2011 and is estimated to be $8,124,000 in 2012, $7,321,000 in 2013, $6,926,000 in 2014, $5,614,000 in 2015 and $4,150,000 in 2016. Definite lived intangibles are being amortized on a straight-line basis for periods from 3 to 20 years with the majority of the intangibles being amortized over a life of between 10 and 13 years.

9

Warranty Costs - Generally, the Company’s products are covered from the date of sale to the customer by warranties against defects in material and workmanship for various periods depending on the product. Certain components carry a lifetime warranty. A provision for estimated warranty cost is recorded at the time of sale based upon actual experience. The Company continuously assesses the adequacy of its product warranty accrual and makes adjustments as needed. Historical analysis is primarily used to determine the Company’s warranty reserves. Claims history is reviewed and provisions are adjusted as needed. However, the Company does consider other events, such as a product recall, which could warrant additional warranty reserve provision. No material adjustments to warranty reserves were necessary in the first six months of 2011.

The following is a reconciliation of the changes in accrued warranty costs for the reporting period (in thousands):

Balance as of January 1, 2011	$	18,252
Warranties provided during the period		4,617
Settlements made during the period		(5,107	)
Changes in liability for pre-existing warranties during the period, including expirations		1,895
Balance as of June 30, 2011	$	19,657

Long-Term Debt - On May 9, 2008, Staff Position APB 14-1, Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement) (FSP APB 14-1) as codified in Debt with Conversion and Other Options, ASC 470-20, was issued to provide clarification of the accounting for convertible debt that can be settled in cash upon conversion. The FASB believed this clarification was needed because the accounting that was being applied for convertible debt prior to FSP APB 14-1 did not fully reflect the true economic impact on the issuer since the conversion option was not captured as a borrowing cost and its full dilutive effect was not included in earnings per share. ASC 470-20 required separate accounting for the liability and equity components of the convertible debt in a manner that would reflect Invacare’s nonconvertible debt borrowing rate. Accordingly, the Company initially split the total debt amount of $135,000,000 attributable to its 4.125% Convertible Senior Subordinated Debentures due 2027 into a convertible debt amount of $75,988,000 and a stockholders’ equity (debt discount) amount of $59,012,000 as of the retrospective adoption date of February 12, 2007 and is accreting the resulting debt discount as interest expense over a ten year life. The Consolidated Balance Sheet as of June 30, 2011 reflects a decrease in long-term debt of $9,708,000 and a deferred tax liability of $3,398,000 compared to comparable amounts of $25,137,000 and $8,798,000, respectively, as of December 31, 2010.

During the six months ended June 30, 2011, the Company repurchased $45,814,000 ($30,385,000 reduction of debt and $15,429,000 reduction of equity) principal amount of its 4.125% Convertible Senior Subordinated Debentures due 2027. The Company retired the debt at a premium above par. In accordance with Convertible Debt, ASC 470-20, the Company utilized the inducement method of accounting to calculate the loss associated with the early retirement of the convertible debt. For the three and six months ended June 30, 2011, the Company recorded pre-tax expense of $11,855,000 and $16,736,000, respectively, related to the loss on the debt extinguishment including the write-off of $792,000 and $1,128,000 of pre-tax of deferred financing fees, which were previously capitalized, for the three and six months ended June 30, 2011.

The Company utilized primarily its cash and cash flows from operations as well as its revolving line of credit to pay down the debt noted above. At June 30, 2011, the Company had outstanding $224,458,000 on its revolving line of credit compared to $184,932,000 as of December 31, 2010.

During the first six months of 2011, the Company entered into interest rate swap agreements to effectively convert a portion of floating rate revolving credit facility debt to fixed rate debt to avoid the risk of changes in market interest rates. Specifically, interest rate swap agreements for notional amounts of $18,000,000 through June 2013, $20,000,000 and $25,000,000 through May 2013 and $15,000,000 through February 2013 were entered into that fix the LIBOR component of the interest rate on that portion of the revolving credit facility debt at rates of 0.625%, 1.08%, 0.73% and 1.05%, respectively, for effective aggregate rates of 2.375%, 2.83%, 2.48% and 2.80%, respectively.

Shareholders’ Equity Transactions - The 2003 Plan allows the Compensation and Management Development Committee of the Board of Directors (the “Committee”) to grant up to 6,800,000 Common Shares in connection with incentive stock options, non-qualified stock options, stock appreciation rights and stock awards (including the use of restricted stock). The maximum aggregate number of Common Shares that may be granted during the term of the 2003 Plan pursuant to all awards, other than stock options, is 1,300,000 Common Shares. The Committee has the authority to determine which employees and directors will receive awards, the amount of the awards and the other terms and conditions of the awards. During the first six months of 2011, the Committee granted non-qualified stock options to purchase 9,496 Common Shares with a term of ten years at the fair market value of the Company’s Common Shares on the date of grant under the 2003 Plan, which vest ratably in annual installments over the four years following the grant date.

Under the terms of the Company’s outstanding restricted stock awards, all of the shares granted vest ratably over the four years after the grant date. Compensation expense of $1,028,000 was recognized related to restricted stock awards in the first six months of 2011 and, as of June 30, 2011, outstanding restricted stock awards totaling 236,870 shares were not yet vested.

10

As of June 30, 2011, there was $12,380,000 of total unrecognized compensation cost from stock-based compensation arrangements granted under the 2003 Plan, which is related to non-vested options and shares, and includes $3,920,000 related to restricted stock awards. The Company expects the compensation expense to be recognized over a four-year period for a weighted-average period of approximately two years.

Stock option activity during the six months ended June 30, 2011 was as follows:

	2011			Weighted Average            Exercise Price
Options outstanding at January 1		4,484,195		$	29.60
Granted		9,496			31.94
Exercised		(176,649	)		23.22
Canceled		(75,872	)		30.79
Options outstanding at June 30		4,241,170		$	29.86
Options price range at June 30	$	10.70 to
	$	47.80
Options exercisable at June 30		2,740,773
Options available for grant at June 30*		2,520,386

* Options available for grant as of June 30, 2011 reduced by net restricted stock award activity of 482,678.

The following table summarizes information about stock options outstanding at June 30, 2011:

	Options Outstanding						Options Exercisable
Exercise Prices	Number Outstanding At  6/30/11		Weighted Average  Remaining Contractual Life		Weighted Average Exercise  Price		Number Exercisable At 6/30/11		Weighted Average Exercise Price
$ 10.70 - $15.00		19,925		1.2 years	$	10.80		19,425	$	10.70
$ 15.00 - $25.00		1,303,926		6.9	$	21.66		670,699	$	22.36
$ 25.01 - $35.00		1,553,228		6.1	$	27.50		686,558	$	30.03
$ 35.01 - $47.80		1,364,091		2.9	$	40.67		1,364,091	$	40.67
Total		4,241,170		5.3	$	29.86		2,740,773	$	33.31

When stock options are awarded, they generally become exercisable over a four-year vesting period whereby options vest in equal installments each year. Options granted with graded vesting are accounted for as single options. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model with assumptions for expected dividend yield, expected stock price volatility, risk-free interest rate and expected life. The assumed expected life is based on the Company’s historical analysis of option history. The expected stock price volatility is also based on actual historical volatility, and expected dividend yield is based on historical dividends as the Company has no current intention of changing its dividend policy.

The 2003 Plan provides that shares granted come from the Company’s authorized but unissued Common Shares or treasury shares. In addition, the Company’s stock-based compensation plans allow employee participants to exchange shares for minimum withholding taxes, which results in the Company acquiring treasury shares.

Pursuant to the Company’s Board of Directors authorized plan to purchase up to 2,000,000 Common Shares, excluding any shares acquired from employees or directors as a result of the exercise of options or vesting of restricted shares pursuant to the Company’s performance plans, the Company purchased a total of 540,900 shares for an aggregate purchase price of $16,213,000 during the first six months of 2011.

Comprehensive Earnings (loss) - Total comprehensive earnings (loss) were as follows (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2011			2010			2011			2010
Net earnings (loss)	$	10,661		$	(611	)	$	18,115		$	2,495
Foreign currency translation gain (loss)		25,560			(60,747	)		60,993			(110,887	)
SERP/DBO amortization of prior service costs and unrecognized losses		(209	)		151			(420	)		308
Current period unrealized gain (loss) on cash flow hedges, net of tax		(15	)		(146	)		(1,299	)		2,367
Total comprehensive earnings (loss)	$	35,997		$	(61,353	)	$	77,389		$	(105,717	)

11

Income Taxes - The Company had an effective tax rate of (29.1)% and 0.8% on earnings before tax for the three and six month periods ended June 30, 2011 compared to an expected rate at the US statutory rate of 35%. The Company’s effective tax rate for the three and six months ended June 30, 2011 was lower than the U.S. federal statutory rate, principally due to foreign taxes recognized at rates below the U.S. statutory rate including a second quarter $5,100,000 ($0.16 per share) tax benefit as a result of a tax settlement in Germany as the German government agreed to follow a European Court of Justice case and a German Tax Court case that impacted an open tax return year. The net impact of tax benefit from countries with valuation allowances on the Company’s effective tax rate was minimal for the first half of 2011. The Company had an effective tax rate of 125.3% and 67.7% on earnings before tax for the three and six month periods ended June 30, 2010, respectively, compared to an expected rate at the U.S. statutory rate of 35%. The Company’s effective tax rate for the three and six month periods ended June 30, 2010 was higher than the U.S. federal statutory rate as a result of the significant negative impact of the Company not being able to record tax benefits related to losses in countries which had tax valuation allowances. The Company continued to be in a loss position in the U.S. principally as a result of recording pre-tax expenses of $11,855,000 and $16,736,000 for the three and six months ended June 30, 2011, respectively, related to the extinguishment of convertible debt at a premium.

Net Earnings Per Common Share - The following table sets forth the computation of basic and diluted net earnings per common share for the periods indicated (amounts in thousands, except per share amounts).

	Three Months Ended          June 30,					Six Months Ended          June 30,
	2011		2010			2011		2010
	(In thousands, except per share data)
Basic
Average common shares outstanding		31,950		32,386			32,062		32,367
Net earnings (loss)	$	10,661	$	(611	)	$	18,115	$	2,495
Net earnings (loss) per common share	$	0.33	$	(0.02	)	$	0.56	$	.08
Diluted
Average common shares outstanding		31,950		32,386			32,062		32,367
Stock options and awards		534		0			442		124
Shares related to convertible debt		522		0			522		178
Average common shares assuming dilution		33,006		32,386			33,026		32,669
Net earnings (loss)	$	10,661	$	(611	)	$	18,115	$	2,495
Net earnings (loss) per common share	$	0.32	$	(0.02	)	$	0.55	$	0.08

At June 30, 2011, 1,387,621 and 1,955,770 shares were excluded from the average common shares assuming dilution for the three and six months ended June 30, 2011, respectively, as they were anti-dilutive since the majority of the anti-dilutive shares were granted at an exercise price of $41.87, which was higher than the average fair market value prices of $32.48 and $31.12, respectively. At June 30, 2010, 3,213,910 and 2,780,343 shares were excluded from the average common shares assuming dilution for the three and six months ended June 30, 2010 as they were anti-dilutive since the majority of the anti-dilutive shares were granted at an exercise price of $41.87, which was higher than the average fair market value prices of $24.59 and $25.76, respectively. The Company included the impact of 522,000 shares, for both the three and six months ended June 30, 2011, necessary to settle the conversion spread related to the Company’s 4.125% Senior Subordinated Convertible Debentures due 2027 compared to zero and 302,000 shares for the three and six months ended June 30, 2010. This is attributable to the Company’s average stock price during the first three and six months of both years being greater than the conversion price of $24.79, established under the indenture governing the convertible debentures. The dilutive impact of the convertible debt on diluted earnings per share is directly affected by changes in the Company’s stock price and thus increased dilution in the future is possible if the Company’s stock price increases.

Concentration of Credit Risk - The Company manufactures and distributes durable medical equipment and supplies to the home health care, retail and extended care markets. The Company performs credit evaluations of its customers’ financial condition. In December 2000, Invacare entered into an agreement with DLL, a third party financing company, to provide the majority of future lease financing to Invacare’s North America customers. The DLL agreement provides for direct leasing between DLL and the Invacare customer. The Company retains a recourse obligation to DLL, which was $25,028,000 at June 30, 2011, for events of default under the contracts, which total $68,630,000 at June 30, 2011. Guarantees, ASC 460, requires the Company to record a guarantee liability as it relates to the limited recourse obligation. As such, the Company has recorded a liability of $598,000 for this guarantee obligation within accrued expenses. The Company monitors the collections status of these contracts and has provided amounts for estimated losses in its allowances for doubtful accounts in accordance with Receivables, ASC 310-10-05-4. Credit losses are provided for in the financial statements.

12

Substantially all of the Company’s receivables are due from health care, medical equipment providers and long term care facilities located throughout the United States, Australia, Canada, New Zealand and Europe. A significant portion of products sold to dealers, both foreign and domestic, is ultimately funded through government reimbursement programs such as Medicare and Medicaid. In addition, the Company has also seen a significant shift in reimbursement to customers from managed care entities. As a consequence, changes in these programs can have an adverse impact on dealer liquidity and profitability. In addition, reimbursement guidelines in the home health care industry have a substantial impact on the nature and type of equipment an end user can obtain as well as the timing of reimbursement and, thus, affect the product mix, pricing and payment patterns of the Company’s customers.

Derivatives -Derivatives and Hedging, ASC 815, requires companies to recognize all derivative instruments in the consolidated balance sheet as either assets or liabilities at fair value. The accounting for changes in fair value of a derivative is dependent upon whether or not the derivative has been designated and qualifies for hedge accounting treatment and the type of hedging relationship. For derivatives designated and qualifying as hedging instruments, the Company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation.

Cash Flow Hedging Strategy

The Company uses derivative instruments in an attempt to manage its exposure to commodity price risk, foreign currency exchange risk and interest rate risk. Foreign exchange contracts are used to manage the price risk associated with forecasted sales denominated in foreign currencies and the price risk associated with forecasted purchases of inventory over the next twelve months. Interest rate swaps are, at times, utilized to manage interest rate risk associated with the Company’s fixed and floating-rate borrowings.

The Company recognizes its derivative instruments as assets or liabilities in the consolidated balance sheet measured at fair value. A majority of the Company’s derivative instruments are designated and qualify as cash flow hedges. Accordingly, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. The remaining gain or loss on the derivative instrument in excess of the cumulative change in the fair value of the hedged item, if any, is recognized in current earnings during the period of change.

Effective April 5, 2011, the Company entered into an amendment to its credit agreement that, among other things, reduced the applicable interest rate related to both LIBOR and Base Rate option borrowings by 75 basis points. During the first six months of 2011, the Company entered into interest rate swap agreements to effectively convert a portion of floating rate revolving credit facility debt to fixed rate debt to avoid the risk of changes in market interest rates. Specifically, interest rate swap agreements for notional amounts of $18,000,000 through June 2013, $20,000,000 and $25,000,000 through May 2013 and $15,000,000 through February 2013 were entered into that fix the LIBOR component of the interest rate on that portion of the revolving credit facility debt at rates of 0.625%, 1.08%, 0.73% and 1.05%, respectively, for effective aggregate rates of 2.375%, 2.83%, 2.48% and 2.80%, respectively. The gains and or losses on interest rate swaps are reflected in interest expense on the consolidated statement of earnings. The Company was not a party to any interest rate swap agreements during 2010.

To protect against increases/decreases in forecasted foreign currency cash flows resulting from inventory purchases/sales over the next year, the Company utilizes foreign currency forward contracts to hedge portions of its forecasted purchases/sales denominated in foreign currencies. The gains and losses are included in cost of products sold and selling, general and administrative expenses on the consolidated statement of earnings. If it is later determined that a hedged forecasted transaction is unlikely to occur, any gains or losses on the forward contracts associated with the forecasted transactions that are no longer probable of occurring would be reclassified from other comprehensive income into earnings. The Company does not expect any material amount of hedge ineffectiveness related to forward contract cash flow hedges during the next twelve months.

The Company has historically not recognized any material amount of ineffectiveness related to forward contract cash flow hedges because the Company generally limits it hedges to between 60% and 90% of total forecasted transactions for a given entity’s exposure to currency rate changes and the transactions hedged are recurring in nature. Furthermore, the majority of the hedged transactions are related to intercompany sales and purchases for which settlement occurs on a specific day each month. Forward contracts with a total notional amount in USD of $49,223,000 and $88,605,000 matured during the three and six months ended June 30, 2011, respectively, compared to forward contracts with a total notional amount in USD of $41,683,000 and $82,081,000 which matured during the three and six months ended June 30, 2010, respectively.

13

Foreign exchange forward contracts qualifying and designated for hedge accounting treatment were as follows (in thousands USD):

	June 30, 2011					December 31, 2010
	Notional Amount		Unrealized Gain (Loss)			Notional Amount		Unrealized Gain (Loss)
USD / AUD	$	1,536	$	(231	)	$	3,072	$	(223	)
USD / CAD		16,839		(30	)		32,974		(14	)
USD / CNY		6,444		33			0		0
USD / EUR		17,084		(1,078	)		32,419		927
USD / GBP		2,006		(84	)		4,212		86
USD / NZD		7,160		578			9,577		202
USD / SEK		5,376		30			10,395		95
USD / MXP		3,486		149			0		0
EUR / AUD		679		(27	)		0		0
EUR / CHF		2,677		(150	)		8,768		54
EUR / GBP		13,367		193			18,068		(577	)
EUR / SEK		6,131		194			8,045		92
EUR / NOK		2,287		(24	)		0		0
EUR / NZD		4,384		171			2,630		5
GBP / CHF		957		36			770		(3	)
GBP / SEK		1,326		65			2,014		(43	)
GBP / DKK		704		12			1,016		(27	)
CHF / SEK		239		(7	)		6,937		(3	)
DKK / CHF		316		(17	)		514		1
DKK / NOK		894		(10	)		0		0
DKK / SEK		3,952		9			1,465		18
NOK / SEK		413		(3	)		0		0
	$	98,257	$	(191	)	$	142,876	$	590

Fair Value Hedging Strategy

In 2011 and 2010, the Company did not utilize any derivatives designated as fair value hedges. However, the Company has in the past utilized fair value hedges in the form of forward contracts to manage the foreign exchange risk associated with certain firm commitments and has entered into interest rate swaps to effectively convert fixed-rate debt to floating-rate debt in an attempt to avoid paying higher than market interest rates. For derivative instruments designated and qualifying as fair value hedges, the gain or loss on the derivative instrument as well as the offsetting gain or loss on the hedged item associated with the hedged risk are recognized in the same line item associated with the hedged item in earnings.

Derivatives Not Qualifying or Designated for Hedge Accounting Treatment

The Company utilizes foreign currency forward or option contracts that do not qualify for hedge accounting treatment in an attempt to manage the risk associated with the conversion of earnings in foreign currencies into U.S. Dollars. While these derivative instruments do not qualify for hedge accounting treatment in accordance with ASC 815, these derivatives do provide the Company with a means to manage the risk associated with currency translation. These instruments are recorded at fair value in the consolidated balance sheet and any gains or losses are recorded as part of earnings in the current period. An immaterial gain was recorded by the Company for the three and six months ended June 30, 2011, respectively, related to these derivatives not qualifying for hedge accounting treatment, while no such derivatives existed for the three and six months ended June 30, 2010.

The Company also utilizes foreign currency forward contracts that are not designated as hedges in accordance with ASC 815 although they could qualify for hedge accounting treatment. These contracts are entered into to eliminate the risk associated with the settlement of short-term intercompany trading receivables and payables between Invacare Corporation and its foreign subsidiaries. The currency forward contracts are entered into at the same time as the intercompany receivables or payables are created so that upon settlement, the gain/loss on the settlement is offset by the gain/loss on the foreign currency forward contract. No material net gain or loss was realized by the Company for the three or six month periods ended June 30, 2011 and 2010, respectively, related to these forward contracts and the associated short-term intercompany trading receivables and payables.

14

Foreign exchange forward contracts not qualifying or designated for hedge accounting treatment entered into in and outstanding as of June 30, 2011 and 2010 were as follows (in thousands USD):

	June 30, 2011					June 30, 2010
	Notional Amount		Gain  (Loss)			Notional Amount		Gain  (Loss)
CAD / USD	$	0	$	0		$	9,350	$	(231	)
CHF / USD		909		43			0		0
CHF / GBP		0		0			0		0
NZD / USD		0		0			13,396		(174	)
NOK / USD		6,252		212			0		0
SEK / USD		0		0			3,187		22
DKK / USD		0		0			2,539		(76	)
DKK / NOK		149		(2	)		0		0
EUR / GBP		0		0			1,544		(68	)
EUR / SEK		19		0			118		(6	)
EUR / CAD		20,000		327			0		0
EUR / USD		0		8			11,912		(290	)
EUR / NZD		159		(2	)		0		0
	$	27,488	$	586		$	42,046	$	(823	)

The fair values of the Company’s derivative instruments were as follows (in thousands):

	June 30, 2011					December 31, 2010
	Assets		Liabilities			Assets		Liabilities
Derivatives designated as hedging instruments under ASC 815
Foreign currency forward contracts	$	2,990	$	(3,181	)	$	2,518	$	1,928
Interest rate swap contracts		0		(416	)		0		0
Derivatives not designated as hedging instruments under ASC 815
Foreign currency forward contracts		590		(4	)		366		1
Total derivatives	$	3,580	$	(3,601	)	$	2,884	$	1,929

The fair values of the Company’s foreign currency forward assets and liabilities are included in Other Current Assets and Accrued Expenses, respectively in the Consolidated Balance Sheets.

15

The effect of derivative instruments on the Statement of Earnings and Other Comprehensive Income (OCI) was as follows (in thousands):

Derivatives in ASC 815 cash flow hedge relationships	Amount of Gain   (Loss) Recognized in   OCI on Derivatives (Effective Portion)			Amount of Gain (Loss)   Reclassified from Accumulated OCI into Income (Effective Portion)			Amount of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion and Amount Excluded from Effectiveness Testing)
Quarter ended June 30, 2011:
Foreign currency forward contracts	$	410		$	(5	)	$	(10	)
Interest rate swap contracts		(287	)		0			0
	$	123		$	(5	)	$	(10	)
Six months ended June 30, 2011:
Foreign currency forward contracts	$	(838	)	$	57		$	(4	)
Interest rate swap contracts		(416	)		0			0
	$	(1,254	)	$	57		$	(4	)
Quarter ended June 30, 2010:
Foreign currency forward contracts	$	(918	)	$	840		$	(65	)
Six months ended June 30, 2010:
Foreign currency forward contracts	$	1,338		$	779		$	(39	)

Derivatives not designated as hedging instruments under ASC 815	Amount of Gain (Loss) Recognized in Income on Derivatives
Quarter ended June 30, 2011:
Foreign currency forward contracts	$	(237	)
Six months ended June 30, 2011:
Foreign currency forward contracts	$	586
Quarter ended June 30, 2010:
Foreign currency forward contracts	$	(1,144	)
Six months ended June 30, 2010:
Foreign currency forward contracts	$	(823	)

The gains or losses recognized as the result of the settlement of cash flow hedge foreign currency forward contracts are recognized in net sales for hedges of inventory sales or cost of product sold for hedges of inventory purchases. For the three and six months ended June 30, 2011, net sales were increased by $1,041,000 and $1,254,000 and cost of product sold was increased by $1,046,000 and $1,197,000 for a net realized loss of $5,000 and gain of $57,000, respectively. For the quarter and six months ended June 30 2010, net sales were increased by $426,000 and $540,000, respectively, and cost of product sold was decreased by $414,000 and $239,000 for net realized gains of $840,000 and $779,000, respectively. As the result of swap agreements outstanding in 2011, losses of $77,000 and $118,000 were recorded for the three and six months ended June 30, 2011 which were recorded in interest expense. No swap agreements were outstanding in 2010.

16

A loss of $227,000 and a gain of $590,000 was recognized in selling, general and administrative (SG&A) expenses for the three and six months ended June 30, 2011, respectively, compared to losses of $1,144,000 and $823,000 for the three and six months ended June 30, 2010 on foreign currency forward contracts not designated as hedging instruments, which were substantially offset by foreign currency gains/losses also recorded in SG&A expenses on the intercompany trade payables for which the derivatives were entered into to offset. In addition, losses of $10,000 and $4,000 were recognized for the three and six months ended June 30, 2011, respectively, compared to losses of $65,000 and $39,000 for the three and six months ended June 30, 2010, respectively, related to derivatives no longer qualifying for hedge accounting treatment as the forecasted transactions hedged by those derivatives were no longer probable of occurring and as a result, the hedging relationship was ineffective.

Fair Value Measurements - Pursuant to ASC 820, the inputs used to derive the fair value of assets and liabilities are analyzed and assigned a level of I, II or III, with level I being the highest and level III being the lowest in the hierarchy. Level I inputs are quoted prices in active markets for identical assets or liabilities. Level II inputs are quoted prices for similar assets or liabilities in active markets: quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. Level III inputs are based on valuations derived from valuation techniques in which one or more significant inputs are unobservable.

The following table provides a summary of the Company’s assets and liabilities that are measured on a recurring basis (in thousands):

				Basis for Fair Value Measurements at Reporting  Date
				Quoted Prices in  Active Markets for Identical Assets / (Liabilities)		Significant Other   Observable  Inputs			Significant Other        Unobservable Inputs
	Total			Level I		Level II			Level III
June 30, 2011
Forward Exchange Contracts-net	$	395		$	0	$	395		$	0
Swaps		(416	)		0		(416	)		0
December 31, 2010
Forward Exchange Contracts-net	$	955		$	0	$	955		$	0

Forward Contracts: The Company operates internationally and as a result is exposed to foreign currency fluctuations. Specifically, the exposure includes intercompany trade receivables/payables and loans as well as third party sales or purchases. In an attempt to reduce this exposure, foreign currency forward contracts are utilized and accounted for as hedging instruments. The forward contracts are used to hedge various currencies. The Company does not use derivative financial instruments for speculative purposes. Fair values for the Company’s foreign exchange forward contracts are based on quoted market prices for contracts with similar maturities.

The carrying amounts and fair values of the Company’s financial instruments at June 30, 2011 and December 31, 2010 are as follows (in thousands):

	June 30, 2011						December 31, 2010
	Carrying     Value			Fair Value			Carrying     Value			Fair Value
Cash and cash equivalents	$	38,162		$	38,162		$	48,462		$	48,462
Other investments		1,590			1,590			1,588			1,588
Installment receivables, net		7,281			7,281			5,672			5,672
Long-term debt (including current maturities of long-term debt) *		(255,728	)		(264,489	)		(246,064	)		(264,382	)
Forward contracts in other current assets		3,580			3,580			2,884			2,884
Interest rate swap agreements in accrued expenses		(416	)		(416	)		0			0
Forward contracts in accrued expenses		(3,185	)		(3,185	)		(1,929	)		(1,929	)

* The carrying amounts and fair values exclude convertible debt classified as equity in accordance with FSP APB 14-1 ($9,708,000 and $25,137,000 as of June 30, 2011 and December 31, 2010, respectively).

17

Business Segments - The Company operates in five primary business segments: North America/Home Medical Equipment (NA/HME), Invacare Supply Group (ISG), Institutional Products Group (IPG), Europe and Asia/Pacific. The NA/HME segment sells each of three primary product lines, which includes: standard, rehab and respiratory products. Invacare Supply Group sells distributed product and the Institutional Products Group sells health care furnishings and accessory products. Europe and Asia/Pacific sell the same product lines as NA/HME and the Institutional Products Group. Each business segment sells to the home health care, retail and extended care markets.

The Company evaluates performance and allocates resources based on profit or loss from operations before income taxes for each reportable segment. The accounting policies of each segment are the same as those described in the summary of significant accounting policies for the Company’s consolidated financial statements. Intersegment sales and transfers are based on the costs to manufacture plus a reasonable profit element. Therefore, intercompany profit or loss on intersegment sales and transfers is not considered in evaluating segment performance, except for Asia/Pacific due to its significant intercompany sales volume.

The information by segment is as follows (in thousands):

	Three Months Ended June  30,						Six Months Ended June  30,
	2011			2010			2011			2010
Revenues from external customers
North America / HME	$	198,732		$	190,089		$	384,345		$	365,075
Invacare Supply Group		75,737			72,826			149,783			142,544
Institutional Products Group		26,113			22,700			53,754			44,978
Europe		141,860			123,105			263,247			240,833
Asia/Pacific		23,970			22,108			43,781			39,638
Consolidated	$	466,412		$	430,828		$	894,910		$	833,068
Intersegment Revenues
North America / HME	$	22,334		$	22,395		$	43,201		$	43,343
Invacare Supply Group		24			19			40			32
Institutional Products Group		1,045			1,540			3,181			2,997
Europe		2,786			2,491			4,632			5,333
Asia/Pacific		9,997			8,548			17,943			15,784
Consolidated	$	36,186		$	34,993		$	68,997		$	67,489
Restructuring charges before income taxes
North America / HME	$	0		$	0		$	0		$	0
Invacare Supply Group		0			0			0			0
Institutional Products Group		0			0			0			0
Europe		431			0			431			0
Asia/Pacific		0			0			0			0
Consolidated	$	431		$	0		$	431		$	0
Earnings (loss) before income taxes
North America / HME	$	13,324		$	10,479		$	26,576		$	22,026
Invacare Supply Group		1,489			1,331			2,684			2,199
Institutional Products Group		3,764			3,331			7,885			5,138
Europe		9,480			9,293			14,440			13,827
Asia/Pacific		1,842			2,534			2,893			3,351
All Other *		(21,638	)		(24,554	)		(36,213	)		(38,821	)
Consolidated	$	8,261		$	2,414		$	18,265		$	7,720

* “All Other” consists of un-allocated corporate selling, general and administrative costs, which do not meet the quantitative criteria for determining reportable segments. In addition, “All Other” loss before income taxes includes loss on debt extinguishment including finance charges and associated fees.

18

Charges Related to Restructuring Activities – During the quarter ended June 30, 2011, the Company announced that it intends to close a European assembly facility as part of the Company’s ongoing globalization initiative to reduce complexity within the Company’s global supply chain footprint. The Company intends to transfer assembly activities to other Company facilities or outsource them to third parties. To date, the Company has recorded restructuring charges of $431,000 for severance related to the European segment, which are expected to be utilized during the next twelve months. The Company will have additional charges related to the closing of the facility, as it is not expected to be complete until the first quarter of 2012.

Contingencies – In the ordinary course of its business, the Company is a defendant in a number of lawsuits, primarily product liability actions in which various plaintiffs seek damages for injuries allegedly caused by defective products. All of the product liability lawsuits have been referred to the company’s captive insurance company and/or excess insurance carriers and generally are contested vigorously. The coverage territory of the Company’s insurance is worldwide with the exception of those countries with respect to which, at the time the product is sold for use or at the time a claim is made, the U.S. government has suspended or prohibited diplomatic or trade relations. The amount recorded for identified contingent liabilities is based on estimates. Amounts recorded are reviewed periodically and adjusted to reflect additional technical and legal information that becomes available. Actual costs to be incurred in future periods may vary from the estimates, given the inherent uncertainties in evaluating certain exposures. Subject to the imprecision in estimating future contingent liability costs, the company does not expect that any sum it may have to pay in connection with these matters in excess of the amounts recorded will have a materially adverse effect on its financial position, results of operations or liquidity.

As a medical device manufacturer, the company is subject to extensive government regulation, including numerous laws directed at preventing fraud and abuse and laws regulating reimbursement under various government programs. The marketing, invoicing, documentation and other practices of health care suppliers and manufacturers are all subject to government scrutiny. Violations of law, regulations, licensing or registration requirements can result in administrative, civil and criminal penalties and sanctions, including disqualification from the licensing or certification required for the sale of products or for the reimbursement therefore, in the U.S., Canada, Australia, New Zealand, relevant European countries and China, which could have a material adverse effect on the Company’s business. By way of further example, the Food & Drug Administration (FDA) regulates virtually all aspects of a medical device’s development, testing, manufacturing, labeling, promotion, distribution and marketing in the U.S. Any failure by the Company to comply with the regulatory requirements of the FDA or other applicable regulatory requirements may subject the Company to administrative or judicially imposed sanctions. These sanctions include warning letters, civil penalties, criminal penalties, injunctions, consent decrees, product seizures or detention, product recalls and total or partial suspensions of production.

The Company continues to work on the improvements and corrective actions that it is making in response to regulatory compliance concerns raised by the FDA, including as a result of the FDA warning letter that was previously disclosed by the Company.

Any of the above contingencies could have an adverse impact on the company’s financial condition or results of operations.

Supplemental Guarantor Information - Effective February 12, 2007, substantially all of the domestic subsidiaries (the “Guarantor Subsidiaries”) of the Company became guarantors of the indebtedness of Invacare Corporation under its 4.125% Senior Subordinated Debentures due 2027 (the “Convertible Notes”) with an initial aggregate principal amount of $135,000,000. The majority of the Company’s subsidiaries, which are primarily foreign subsidiaries of the Company, are not guaranteeing the repayment of the Convertible Notes (the “Non-Guarantor Subsidiaries”). Each of the Guarantor Subsidiaries has fully and unconditionally guaranteed, on a joint and several basis, to pay principal, premium, and interest related to the Convertible Notes and each of the Guarantor Subsidiaries are directly or indirectly wholly-owned subsidiaries of the Company.

Presented below are the consolidating condensed financial statements of Invacare Corporation (Parent), its combined Guarantor Subsidiaries and combined Non-Guarantor Subsidiaries with their investments in subsidiaries accounted for using the equity method. The Company does not believe that separate financial statements of the Guarantor Subsidiaries are material to investors and accordingly, separate financial statements and other disclosures related to the Guarantor Subsidiaries are not presented.

19

CONSOLIDATING CONDENSED STATEMENTS OF OPERATIONS

(in thousands) Three month period ended June 30, 2011	The Company     (Parent)			Combined Guarantor   Subsidiaries		Combined Non-Guarantor   Subsidiaries			Eliminations			Total
Net sales	$	97,746		$	195,578	$	198,509		$	(25,421	)	$	466,412
Cost of products sold		71,276			151,004		134,329			(25,115	)		331,494
Gross Profit		26,470			44,574		64,180			(306	)		134,918
Selling, general and administrative expenses		36,451			15,924		49,299			10,743			112,417
Loss on debt extinguishment including debt finance charges and associated fees		11,855			0		0			0			11,855
Charges related to restructuring activities		0			0		431			0			431
Income (loss) from equity investee		33,627			13,727		1,078			(48,432	)		0
Interest expense - net		650			404		900			0			1,954
Earnings (loss) before Income Taxes		11,141			41,973		14,628			(59,481	)		8,261
Income taxes		480			100		(2,980	)		0			(2,400	)
Net Earnings (loss)	$	10,661		$	41,873	$	17,608		$	(59,481	)	$	10,661
Three month period ended June 30, 2010
Net sales	$	101,403		$	184,190	$	171,337		$	(26,102	)	$	430,828
Cost of products sold		72,635			143,762		113,978			(26,037	)		304,338
Gross Profit		28,768			40,428		57,359			(65	)		126,490
Selling, general and administrative expenses		35,501			28,367		40,553			0			104,421
Loss on debt extinguishment including debt finance charges and associated fees		14,048			0		0			0			14,048
Income (loss) from equity investee		25,203			7,239		(395	)		(32,047	)		0
Interest expense - net		4,703			202		702			0			5,607
Earnings (loss) before Income Taxes		(281	)		19,098		15,709			(32,112	)		2,414
Income taxes		330			403		2,292			0			3,025
Net Earnings (loss)	$	(611	)	$	18,695	$	13,417		$	(32,112	)	$	(611	)

20

CONSOLIDATING CONDENSED STATEMENTS OF OPERATIONS

(in thousands) Six month period ended June 30, 2011	The     Company     (Parent)		Combined Guarantor   Subsidiaries		Combined Non- Guarantor Subsidiaries			Eliminations			Total
Net sales	$	189,978	$	385,204	$	369,323		$	(49,595	)	$	894,910
Cost of products sold		137,614		300,055		248,690			(49,373	)		636,986
Gross Profit		52,364		85,149		120,633			(222	)		257,924
Selling, general and administrative expenses		69,151		30,117		94,809			24,117			218,194
Loss on debt extinguishment including debt finance charges and associated fees		16,736		0		0			0			16,736
Charges related to restructuring activities		0		0		431			0			431
Income (loss) from equity investee		54,451		18,061		1,056			(73,568	)		0
Interest expense - net		1,713		781		1,804			0			4,298
Earnings (loss) before Income Taxes		19,215		72,312		24,645			(97,907	)		18,265
Income taxes		1,100		200		(1,150	)		0			150
Net Earnings (loss)	$	18,115	$	72,112	$	25,795		$	(97,907	)	$	18,115
Six month period ended June 30, 2010
Net sales	$	195,241	$	355,437	$	332,782		$	(50,392	)	$	833,068
Cost of products sold		138,773		278,970		221,523			(50,401	)		588,865
Gross Profit		56,468		76,467		111,259			9			244,203
Selling, general and administrative expenses		67,214		53,202		85,781			0			206,197
Loss on debt extinguishment including debt finance charges and associated fees		18,434		0		0			0			18,434
Income (loss) from equity investee		42,447		8,834		(384	)		(50,897	)		0
Interest expense - net		9,779		309		1,764			0			11,852
Earnings (loss) before Income Taxes		3,488		31,790		23,330			(50,888	)		7,720
Income taxes		993		553		3,679			0			5,225
Net Earnings (loss)	$	2,495	$	31,237	$	19,651		$	(50,888	)	$	2,495

21

CONSOLIDATING CONDENSED BALANCE SHEETS

(in thousands) June 30, 2011	The     Company     (Parent)		Combined Guarantor     Subsidiaries		Combined  Non-Guarantor  Subsidiaries		Eliminations			Total
Assets
Current Assets
Cash and cash equivalents	$	4,706	$	1,976	$	31,480	$	0		$	38,162
Trade receivables, net		90,870		71,289		106,594		0			268,753
Installment receivables, net		0		1,252		4,725		0			5,977
Inventories, net		41,334		41,579		107,399		(1,500	)		188,812
Deferred income taxes		3,431		0		2,589		0			6,020
Other current assets		12,238		5,775		32,839		(1,318	)		49,534
Total Current Assets		152,579		121,871		285,626		(2,818	)		557,258
Investment in subsidiaries		1,605,100		568,810		0		(2,173,910	)		0
Intercompany advances, net		78,729		815,660		201,985		(1,096,374	)		0
Other Assets		42,768		1,049		1,356		0			45,173
Other Intangibles		1,036		7,956		63,279		0			72,271
Property and Equipment, net		46,530		12,565		74,942		0			134,037
Goodwill		5,023		34,386		514,095		0			553,504
Total Assets	$	1,931,765	$	1,562,297	$	1,141,283	$	(3,273,102	)	$	1,362,243
Liabilities and Shareholders’ Equity
Current Liabilities
Accounts payable	$	79,159	$	17,657	$	63,806	$	0		$	160,622
Accrued expenses		31,346		22,129		82,131		(1,318	)		134,288
Accrued income taxes		928		0		477		0			1,405
Short-term debt and current maturities of long-term obligations		7,609		68		754		0			8,431
Total Current Liabilities		119,042		39,854		147,168		(1,318	)		304,746
Long-Term Debt		234,798		0		12,499		0			247,297
Other Long-Term Obligations		51,445		1,100		54,710		0			107,255
Intercompany advances, net		823,535		175,036		97,806		(1,096,377	)		0
Total Shareholders’ Equity		702,945		1,346,307		829,100		(2,175,407	)		702,945
Total Liabilities and Shareholders’ Equity	$	1,931,765	$	1,562,297	$	1,141,283	$	(3,273,102	)	$	1,362,243

22

CONSOLIDATING CONDENSED BALANCE SHEETS

(in thousands) December 31, 2010	The     Company     (Parent)		Combined Guarantor     Subsidiaries		Combined  Non-Guarantor  Subsidiaries		Eliminations			Total
Assets
Current Assets
Cash and cash equivalents	$	4,036	$	2,476	$	41,950	$	0		$	48,462
Trade receivables, net		95,673		68,504		87,827		0			252,004
Installment receivables, net		0		876		3,083		0			3,959
Inventories, net		72,499		39,299		63,873		(1,296	)		174,375
Deferred income taxes		3,289		0		2,489		0			5,778
Other current assets		12,274		6,895		27,685		(5,273	)		41,581
Total Current Assets		187,771		118,050		226,907		(6,569	)		526,159
Investment in subsidiaries		1,489,732		594,690		0		(2,084,422	)		0
Intercompany advances, net		77,990		745,991		226,421		(1,050,402	)		0
Other Assets		42,782		1,881		821		0			45,484
Other Intangibles		1,241		8,590		61,080		0			70,911
Property and Equipment, net		46,791		12,093		71,879		0			130,763
Goodwill		5,023		34,388		467,672		0			507,083
Total Assets	$	1,851,330	$	1,515,683	$	1,054,780	$	(3,141,393	)	$	1,280,400
Liabilities and Shareholders’ Equity
Current Liabilities
Accounts payable	$	73,468	$	14,923	$	55,362	$	0		$	143,753
Accrued expenses		39,090		20,690		75,572		(5,273	)		130,079
Accrued income taxes		5,633		0		2,869		0			8,502
Short-term debt and current maturities of long-term obligations		7,149		83		742		0			7,974
Total Current Liabilities		125,340		35,696		134,545		(5,273	)		290,308
Long-Term Debt		217,164		0		20,926		0			238,090
Other Long-Term Obligations		48,645		1,123		49,823		0			99,591
Intercompany advances, net		807,770		180,743		61,889		(1,050,402	)		0
Total Shareholders’ Equity		652,411		1,298,121		787,597		(2,085,718	)		652,411
Total Liabilities and Shareholders’ Equity	$	1,851,330	$	1,515,683	$	1,054,780	$	(3,141,393	)	$	1,280,400

23

CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS

(in thousands) Six month period ended June 30, 2011	The     Company     (Parent)			Combined Guarantor     Subsidiaries			Combined Non-Guarantor Subsidiaries			Eliminations			Total
Net Cash Provided (Used) by Operating Activities	$	35,442		$	(1,643	)	$	27,314		$	(24,117	)	$	36,996
Investing Activities
Purchases of property and equipment		(3,818	)		(1,807	)		(4,479	)		0			(10,104	)
Proceeds from sale of property and equipment		0			15			22			0			37
(Increase) decrease in other long-term assets		(1,016	)		0			5			0			(1,011	)
Business acquisitions, net of cash acquired		0			0			0			0			(0	)
Other		5			1			(82	)		0			(76	)
Net Cash Used for Investing Activities		(4,829	)		(1,791	)		(4,534	)		0			(11,154	)
Financing Activities
Proceeds from revolving lines of credit and long-term borrowings		227,818			2,934			0			0			230,752
Payments on revolving lines of credit and long-term debt and capital lease obligations		(226,739	)		0			(11,142	)		0			(237,881	)
Proceeds from exercise of stock options		4,101			0			0			0			4,101
Payment of financing costs		(18,116	)		0			0			0			(18,116	)
Payment of dividends		(794	)		0			(24,117	)		24,117			(794	)
Purchase of treasury stock		(16,213	)		0			0			0			(16,213	)
Net Cash Provided (Used) by Financing Activities		(29,943	)		2,934			(35,259	)		24,117			(38,151	)
Effect of exchange rate changes on cash		0			0			2,009			0			2,009
Increase (decrease) in cash and cash equivalents		670			(500	)		(10,470	)		0			(10,300	)
Cash and cash equivalents at beginning of period		4,036			2,476			41,950			0			48,462
Cash and cash equivalents at end of period	$	4,706		$	1,976		$	31,480		$	0		$	38,162

24

CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS

(in thousands) Six month period ended June 30, 2010	The     Company     (Parent)			Combined Guarantor     Subsidiaries			Combined Non- Guarantor  Subsidiaries			Eliminations		Total
Net Cash Provided (Used) by Operating Activities	$	40,095		$	14,764		$	(779	)	$	0	$	54,080
Investing Activities
Purchases of property and equipment		(4,200	)		(246	)		(3,976	)		0		(8,422	)
Proceeds from sale of property and equipment					(2	)		315			0		313
(Increase) decrease in other long-term assets		368			(11	)		456			0		813
Business acquisitions, net of cash acquired					(13,725	)		0			0		(13,725	)
Other		301			(10	)		(514	)		0		(223	)
Net Cash Used for Investing Activities		(3,531	)		(13,994	)		(3,719	)		0		(21,244	)
Financing Activities
Proceeds from revolving lines of credit and long-term borrowings		197,209			0			4,452			0		201,661
Payments on revolving lines of credit and long-term debt and capital lease obligations		(219,847	)		0			0			0		(219,847	)
Proceeds from exercise of stock options		1,002			0			0			0		1,002
Payment of financing costs		(16,549	)		0			0			0		(16,549	)
Payment of dividends		(808	)		0			0			0		(808	)
Net Cash Provided (Used) by Financing Activities		(38,993	)		0			4,452			0		(34,541	)
Effect of exchange rate changes on cash		0			0			(4,591	)		0		(4,591	)
Increase (decrease) in cash and cash equivalents		(2,429	)		770			(4,637	)		0		(6,296	)
Cash and cash equivalents at beginning of period		6,569			2,526			28,406			0		37,501
Cash and cash equivalents at end of period	$	4,140		$	3,296		$	23,769		$	0	$	31,205

25

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis should be read in conjunction with the Company’s Condensed Consolidated Financial Statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the Company’s Current Report on Form 8-K as furnished to the Securities and Exchange Commission on July 28, 2011.

OUTLOOK

Invacare had a strong first half of the year with organic net sales growth, which it expects to continue in the second half of the year. However, the benefits of higher organic net sales growth on earnings may be diluted by two issues. First, the Company’s gross margin declined in the first half of the year related to sales mix favoring lower margin customers and lower margin product lines as well as pricing pressure on certain products. While the Company intends to proactively manage these issues through a variety of initiatives, such as re-focusing its sales force on the total lifecycle cost benefits associated with the HomeFill^® oxygen system, the gross margin for 2011 is now not expected to be as strong as was earlier anticipated. Second, the Company’s results in the second half of 2011 are expected to be impacted by a significantly higher effective tax rate versus the same period last year.

In regards to potential reimbursement risks, there are two notable topics. In the United States, the Company has seen no significant impact related to the first round of National Competitive Bidding (NCB) that went into effect in the nine metropolitan service areas (MSA) on January 1, 2011. While there may be slowness in purchases in these areas, it is hard to measure, since the Company does not have zip code level visibility to either customer’s sales and rental data or Medicare fulfillment data. The Company continues to expect NCB to be neutral to earnings in 2011, but it will remain judicious in its extension of credit to customers in these MSAs. There have been no new updates on Round 2 of NCB, which is scheduled to be implemented in July 2013. In Germany, the government will no longer be reimbursing for stair climber products. The Company will evaluate the potential impact of this decision, as it is unclear if private insurance will continue to pay for the product or if the product will have success as a retail item.

In its efforts to make long-term improvements to the Company, Invacare has two significant globalization projects to note in 2011. First, the Company decided to cease operations at two existing facilities – one in Europe, announced in May, and one small facility in the United States, announced in July – and shift those activities to other Invacare locations and third parties in order to maximize the effectiveness of its supply chain. Once the closures are completed by the end of the first quarter of 2012, annualized savings are expected to approximate $3,500,000. Secondly, since 2010, the Company has been evaluating its product development plans against its globalization product strategy that calls for new products to have a global platform. In doing so, the Company discontinued several projects that did not advance its globalization strategy and redeployed those resources to initiate new projects. This resulted in a decline of new product launches in 2011, but the Company expects to see the benefits in 2012 and beyond with numerous new product launches that will have global market appeal. Organic net sales growth, earnings and cash flow for 2011 are expected to be consistent with the guidance provided in the Company’s July 28, 2011 press release announcing second quarter results. The guidance should be read in conjunction with the information referenced herein under “Risk Factors” and “Forward-Looking Information.”

RESULTS OF OPERATIONS

NET SALES

Net sales for the quarter increased 8.3% to $466,412,000 versus $430,828,000 for the second quarter last year. Foreign currency translation increased net sales by 4.1 percentage points and an acquisition increased net sales by 0.4 of a percentage point. Organic net sales for the quarter increased 3.8% over the same period last year driven by increases in all business segments except Asia/Pacific. For the six months ended June 30, 2011, net sales increased 7.4% to $894,910,000, compared to $833,068,000 for the same period a year ago. Organic sales increased 4.9% driven by increases in all business segments except Asia/Pacific as foreign currency translation increased net sales by 1.9 percentage points while an acquisition increased net sales by 0.6 of a percentage point.

26

North American/Home Medical Equipment (NA/HME)

NA/HME net sales increased 4.5% for the quarter to $198,732,000 as compared to $190,089,000 for the same period a year ago, driven by increases in respiratory and rehab product lines partially offset by declines in standard products. With foreign currency translation increasing net sales by 0.5 of a percentage point and an acquisition impact of 1.0 percentage point, organic net sales for NA/HME increased 3.0% for the quarter. The organic net sales increase was driven primarily by increased net sales of stationary and portable oxygen concentrators, seating and custom manual wheelchairs partially offset by declines in consumer power, HomeFill^® oxygen systems and patient aid products. For the six months ended June 30, 2011, net sales increased 5.3% to $384,345,000 as compared to $365,075,000 for the same period a year ago. Organic sales increased 3.5% as foreign currency increased net sales by 0.5 of a percentage point, while an acquisition increased net sales by 1.3 percentage points in the first half of 2010.

Invacare Supply Group (ISG)

ISG net sales for the quarter increased 4.0% to $75,737,000 compared to $72,826,000 for the same period last year. The net sales increase was in urological, enterals and ostomy product lines. For the first half of 2011, net sales increased 5.1% to $149,783,000 as compared to $142,544,000 for the same period last year.

Institutional Products Group (IPG)

IPG net sales for the second quarter increased by 15.0% to $26,113,000 compared to $22,700,000 last year. Foreign currency translation increased net sales by 0.8 of a percentage point. The net sales increase was driven primarily by strong net sales of institutional beds and dialysis chairs. For the first half of 2011, net sales increased 19.5% to $53,754,000 as compared to $44,978,000 for the same period a year ago.

Europe

For the second quarter, European net sales increased 15.2% to $141,860,000 versus $123,105,000 last year. Foreign currency translation increased net sales by 10.1 percentage points. Organic net sales for the quarter increased by 5.1%, which was driven primarily by increases in the rehab, standard and respiratory product lines. For the first six months of 2011, European net sales increased 9.3% to $263,247,000 compared to $240,833,000 for the same period last year. Organic net sales increased 5.6% for the first half of the year as foreign currency translation increased net sales by 3.7 percentage points.

Asia/Pacific

Asia/Pacific net sales increased 8.4% for the quarter to $23,970,000 as compared to $22,108,000 for the same period a year ago. Foreign currency translation increased net sales by 15.7 percentage points. The organic net sales decrease of 7.3% was driven primarily by the Company’s New Zealand distribution business and by the Company’s subsidiary which produces microprocessor controllers. For the first half of 2011, net sales increased 10.5% to $43,781,000 as compared to $39,638,000 for the same period a year ago. Foreign currency translation increased net sales by approximately 12.7 percentage points resulting in decreased organic net sales of 2.2% for the first half of 2011.

GROSS PROFIT

Gross profit as a percentage of net sales for the three and six-month periods ended June 30, 2011 was 28.9% and 28.8%, respectively, compared to 29.4% and 29.3%, respectively, in the same periods last year. The margin decline was related to sales mix favoring lower margin product lines and lower margin customers, pricing pressures primarily in the Europe segment and increased warranty and commodity costs partially offset by the impact of favorable cost reduction projects and a currency benefit on sourcing in Europe.

For the first half of the year, NA/HME margins as a percentage of net sales decreased by 0.8 of a percentage point compared to the same period last year primarily due to sales mix favoring lower margin product lines and customers, higher freight and warranty costs and pricing pressure in certain products partially offset by volume increases and cost reduction activities. ISG gross margin increased by 0.4 of a percentage point primarily the result of volume increases and cost reduction initiatives partially offset by mix toward lower margin product lines. IPG gross margin increased by 0.2 percentage points due primarily to increased volume and favorable cost reduction programs. In Europe, gross margin as a percentage of net sales decreased by 0.4 percentage points primarily driven by sales mix favoring lower margin product lines and lower margin customers partially offset by increased volume and cost reduction activities. Gross margin, as a percentage of net sales in Asia/Pacific, decreased by 3.5 percentage points, primarily as a result of volume declines and sales mix favoring lower margin product lines.

27

SELLING, GENERAL AND ADMINISTRATIVE

Selling, general and administrative (“SG&A”) expense as a percentage of net sales for the three and six months ended June 30, 2011 was 24.1% and 24.4%, respectively, compared to 24.2% and 24.8%, respectively, for each of the same periods a year ago. The dollar increases in SG&A expense were $7,996,000 and $11,997,000, or 7.7% and 5.8%, respectively, for the quarter and first half of the year, as compared to the same period a year ago. An acquisition increased these expenses by $1,551,000 in the quarter and $3,648,000 in the first half of the year, while foreign currency translation increased these expenses by $5,218,000 in the quarter and $5,787,000 in the first half of the year compared to the same periods a year ago. Excluding the impact of foreign currency translation and an acquisition, SG&A expense increased 1.2% for the quarter and the first half of 2011 as compared to the same periods a year ago. The dollar increase, excluding foreign currency translation and acquisitions, was $1,227,000 and $2,562,000 for the quarter and first half of the year, as compared to the same periods a year ago. The increase in SG&A expense is driven primarily by higher associate costs in all segments and unfavorable foreign currency transactions in Europe and IPG partially offset by a reduction in bad debt expense and insurance costs.

North American/HME SG&A expense decreased $312,000, or 0.5%, for the quarter and increased $3,255,000, or 3.0%, in the first half of 2011 compared to the same periods a year ago. For the quarter, foreign currency translation increased SG&A expense by $278,000 or 0.5% while acquisitions increased SG&A expense by $1,551,000 or 2.7%. For the first half of 2011, foreign currency translation increased SG&A expense by $476,000 or 0.4% while acquisitions increased SG&A by $3,648,000 or 3.4%. The decrease in SG&A expense is primarily attributable to reduced bad debt and insurance costs partially offset by increased associate costs.

Invacare Supply Group SG&A expense increased $536,000, or 7.7%, for the quarter and $1,155,000, or 8.6%, in the first half of 2011 compared to the same periods a year ago, with the year to date increase primarily due to higher distribution and associate costs.

Institutional Products Group SG&A expense increased $530,000, or 12.6%, for the quarter and increased $369,000, or 4.0%, in the first half of 2011 compared to the same periods a year ago. Foreign currency translation increased SG&A expense by $28,000 or 0.7% for the quarter and $85,000 or 0.9% for the first half of the year. Excluding the impact of foreign currency translation, SG&A expense increased 11.9% for the quarter and increased 3.1% for the first half of 2011, respectively, as compared to the same periods last year. The year to date increase is primarily attributable to increased associate costs.

European SG&A expense increased $5,590,000, or 19.1%, for the quarter and $4,600,000, or 7.5%, for the first half of 2011 compared to the same periods a year ago. For the quarter, foreign currency translation increased SG&A by $3,668,000, or 12.5%. For the first half of 2011, foreign currency translation increased SG&A expense by $3,354,000, or 5.4%, respectively. Excluding the impact of foreign currency translation, SG&A expense increased by 6.6% and 2.0% for the quarter and first half of the year, respectively, as compared to the same periods a year ago. The year to date increase is primarily attributable to increased associate costs and unfavorable foreign currency transactions.

Asia/Pacific SG&A expense increased $1,654,000, or 24.1%, for the quarter and $2,618,000, or 19.4%, in the first half of the year compared to the same periods a year ago. For the quarter, foreign currency translation increased SG&A expense by $1,244,000, or 18.1%. For the first half of 2011, foreign currency translation increased SG&A by $1,872,000, or 13.9%. Excluding the impact of foreign currency translation, SG&A expense increased 6.0% and 5.5% for the quarter and first half of 2011, respectively as compared to last year due primarily due to increased expense related to associate costs.

LOSS ON DEBT EXTINGUISHMENT INCLUDING DEBT FINANCE CHARGES AND ASSOCIATED FEES

During the three and six months ended June 30, 2011, the Company repurchased and retired $32,300,000 and $45,814,000 principal amount, respectively, of its 4.125% Convertible Senior Subordinated Debentures due 2027 compared to the three and six months ended June 30, 2010 in which the Company repurchased and retired $59,131,000 and $74,903,000 principal amount, respectively, of debt comprised of $31,131,000 and $45,903,000 principal amount, respectively, related to its 4.125% Convertible Senior Subordinated Debentures due 2027 and $28,000,000 and $29,000,000 principal amount, respectively, related to its 9 3/4% Senior Notes due 2015, respectively. The Company retired the debt at a premium above par. In accordance with Convertible Debt, ASC 470-20, the Company utilized the inducement method of accounting to calculate the loss associated with the early retirement of the convertible debt. For the three and six months ended June 30, 2011, the Company recorded expense of $11,885,000 and $16,736,000, respectively, related to the loss on the debt extinguishment including the write-off of $792,000 and $1,128,000, respectively, of pre-tax deferred financing fees, which were previously capitalized. For the three and six months ended June 30, 2010, the Company recorded expense of $14,048,000 and $18,434,000, respectively, related to the loss on the debt extinguishment including the write-off of $1,471,000 and $1,885,000, respectively, of pre-tax deferred financing fees, which were previously capitalized.

28

CHARGES RELATED TO RESTRUCTURING ACTIVITIES

During the quarter ended June 30, 2011, the Company announced that it intends to close a European assembly facility as part of the Company’s ongoing globalization initiative to reduce complexity within the Company’s global supply chain footprint. The Company plans to transfer the assembly activities to other Company facilities or outsource them to third parties. To date, the Company has recorded restructuring charges of $431,000 for severance related to the European segment, which are expected to be utilized during the next twelve months. The Company will have additional charges related to the closing of the facility, as it is not expected to be complete until the first quarter of 2012.

INTEREST

Interest expense decreased $3,537,000 and $7,318,000 for the second quarter and first half of 2011, respectively, compared to the same periods last year due to lower debt levels. Interest income for the second quarter and first half of 2011 increased $116,000 and $236,000, respectively, compared to the same periods last year, which was primarily the result of higher financing charges.

INCOME TAXES

The Company had an effective tax rate of (29.1)% and 0.8% on earnings before tax for the three and six month periods ended June 30, 2011 compared to an expected rate at the US statutory rate of 35%. The Company’s effective tax rate for the three and six months ended June 30, 2011 was lower than the U.S. federal statutory rate, principally due to foreign taxes recognized at rates below the U.S. statutory rate including a second quarter $5,100,000 ($0.16 per share) tax benefit as a result of a tax settlement in Germany as the German government agreed to follow a European Court of Justice case and a German Tax Court case that impacted an open tax return year. The net impact of tax benefit from countries with valuation allowances on the Company’s effective tax rate was minimal for the first half of 2011. The Company had an effective tax rate of 125.3% and 67.7% on earnings before tax for the three and six month periods ended June 30, 2010, respectively, compared to an expected rate at the U.S. statutory rate of 35%. The Company’s effective tax rate for the three and six month periods ended June 30, 2010 was higher than the U.S. federal statutory rate as a result of the significant negative impact of the Company not being able to record tax benefits related to losses in countries which had tax valuation allowances. The Company continued to be in a loss position in the U.S. principally as a result of recording pre-tax expenses of $11,855,000 and $16,736,000 for the three and six months ended June 30, 2011, respectively, related to the extinguishment of convertible debt at a premium.

LIQUIDITY AND CAPITAL RESOURCES

The Company continues to maintain an adequate liquidity position through its unused bank lines of credit (see Long-Term Debt in the Notes to Consolidated Financial Statements included in this report) and working capital management. The Company maintains various bank lines of credit to finance its worldwide operations.

The Company’s total debt outstanding, inclusive of the debt discount included in equity in accordance with FSB APB 14-1, decreased by $5,765,000 from $271,201,000 as of December 31, 2010 to $265,436,000 as of June 30, 2011, primarily as a result of the generation of cash flow and utilization of cash to pay down debt. The Company’s balance sheet reflects the impact of ASC 470-20, which reduced debt and increased equity by $9,708,000 and $25,137,000 as of June 30, 2011 and December 31, 2010, respectively. The debt discount decreased $10,531,000 and $15,429,000 during the quarter and first half of 2011, primarily as a result of the extinguishment of convertible debt. The Company’s cash and cash equivalents were $38,162,000 at June 30, 2011, down from $48,462,000 at the end of the year. At June 30, 2011, the Company had outstanding $224,458,000 on its revolving line of credit compared to $184,932,000 as of December 31, 2010.

The Company’s senior secured revolving credit agreement (the “Credit Agreement”) provides for a $400 million senior secured revolving credit facility maturing in October 2015. Pursuant to the terms of the Credit Agreement, the Company may from time to time borrow, repay and re-borrow up to an aggregate outstanding amount at any one time of $400 million, subject to customary conditions. The Credit Agreement also provides for the issuance of swing line loans and Borrowings under the Credit Agreement bear interest, at the Company’s election, at (i) the London Inter-Bank Offer Rate (“LIBOR”) plus a margin; or (ii) a Base Rate Option plus a margin. As a result of the amendment to the agreement entered into effective April 5, 2011, the applicable margin is 1.75% per annum for LIBOR loans and 0.75% for the Base Rate Option loans based on the Company’s leverage ratio. In addition to interest, the Company is required to pay commitment fees on the unused portion of the Credit Agreement. The commitment fee rate is 0.30% per annum. Like the interest rate spreads, the commitment fee is subject to adjustment based on the Company’s leverage ratio. The obligations of the borrowers under the Credit Agreement are secured by substantially all of the Company’s U.S. assets and are guaranteed by substantially all of the Company’s material domestic and foreign subsidiaries.

29

The Company may from time to time seek to retire or purchase its 4.125% Convertible Senior Subordinated Debentures due 2027, in open market purchases, privately negotiated transactions or otherwise. Such purchases or exchanges, if any, will depend on prevailing market conditions, the Company’s liquidity requirements, contractual restrictions and other factors. The amounts involved in any such transactions, individually or in the aggregate, may be material. In the first six months of 2011, the Company repurchased and extinguished $45,814,000 principal amount of its Convertible Senior Subordinated Debentures.

The Credit Agreement contains certain covenants that are customary for similar credit arrangements, including covenants relating to, among other things, financial reporting and notification, compliance with laws, preservation of existence, maintenance of books and records, use of proceeds, maintenance of properties and insurance, and limitations on liens, dispositions, issuance of debt, investments, payment of dividends, repurchases of capital stock, acquisitions, transactions with affiliates, and capital expenditures. There also are financial covenants that require the Company to maintain a maximum leverage ratio (consolidated funded indebtedness to consolidated EBITDA, each as defined in the Credit Agreement) of no greater than 3.50 to 1, and a minimum interest coverage ratio (consolidated EBITDA to consolidated interest charges, each as defined in the Credit Agreement) of no less than 3.50 to 1. As of June 30, 2011, the Company’s leverage ratio was 1.84 and the Company’s interest coverage ratio was 13.84 and the Company was in compliance with all covenant requirements. Under the most restrictive covenant of the Company’s borrowing arrangements as of June 30, 2011, the Company had the capacity to borrow up to an additional $175,542,000.

While there is general concern about the potential for rising interest rates, the Company believes that its exposure to interest rate fluctuations is manageable given that portions of the Company’s debt are at fixed rates for extended periods of time, the Company has the ability to utilize swaps to exchange variable rate debt to fixed rate debt, if needed, and the Company’s free cash flow should allow it to absorb any modest rate increases in the months ahead without any material impact on its liquidity or capital resources. During the first six months of 2011, the Company entered into interest rate swap agreements to effectively convert a portion of floating rate revolving credit facility debt to fixed rate debt to avoid the risk of changes in market interest rates. Specifically, interest rate swap agreements for notional amounts of $18,000,000 through June 2013, $20,000,000 and $25,000,000 through May 2013 and $15,000,000 through February 2013 were entered into that fix the LIBOR component of the interest rate on that portion of the revolving credit facility debt at rates of 0.625%, 1.08%, 0.73% and 1.05%, respectively, for effective aggregate rates of 2.375%, 2.83%, 2.48% and 2.80%, respectively.

As is the case for many companies operating in the current economic environment, the Company is exposed to a number of risks. These risks include the possibility that: one or more of the lenders participating in the Company’s revolving credit facility may be unable or unwilling to extend credit to the Company; the third party company that provides lease financing to the Company’s customers may refuse or be unable to fulfill its financing obligations or extend credit to the Company’s customers; interest rates on the Company’s variable rate debt could increase significantly; one or more customers of the Company may be unable to pay for purchases of the Company’s products on a timely basis; one or more key suppliers may be unable or unwilling to provide critical goods or services to the Company; and one or more of the counterparties to the Company’s hedging arrangements may be unable to fulfill its obligations to the Company. Although the Company has taken actions in an effort to mitigate these risks, during periods of economic downturn, the Company’s exposure to these risks increases. Events of this nature may adversely affect the Company’s liquidity or sales and revenues, and therefore have an adverse effect on the Company’s business and results of operations.

CAPITAL EXPENDITURES

The Company had no individually material capital expenditure commitments outstanding as of June 30, 2011. The Company estimates that capital investments for 2011 could approximate $25,000,000 as compared to $17,353,000 in 2010. The Company believes that its balances of cash and cash equivalents, together with funds generated from operations and existing borrowing facilities will be sufficient to meet its operating cash requirements and to fund required capital expenditures for the foreseeable future.

CASH FLOWS

Cash flows provided by operating activities were $36,996,000 for the first half of 2011 compared to $54,080,000 in the first half of 2010. Operating cash flows for the first half of 2011 were lower compared to the same period a year ago as a result of the collection of a $7,800,000 tax receivable in the first quarter of 2010. The current year operating cash flows benefited from improved earnings partially offset by increased accounts receivable and inventory and a reduction in accrued expenses as a result of bonus and tax payments.

30

Cash used for investing activities was $11,154,000 for the first half of 2011 compared to $21,244,000 used in the first half of 2010. The decrease in cash used for investing activities was primarily due to a $13,725,000 acquisition focused on rental of products to skilled nursing and long-term care providers in 2010 partially offset by greater purchases of property, plant and equipment in the first half of 2011 compared to the first half of 2010.

Cash used by financing activities was $38,151,000 for the first half of 2011 compared to cash used of $34,541,000 in the first half of 2010 and reflects the Company’s utilization of cash, including cash generated from operations during the year, as well as utilization of its revolving line of credit during the year principally to retire $45,814,000 principal amount of higher interest convertible senior subordinated debentures. The Company also acquired 540,900 common shares for treasury at an aggregate purchase price of $16,213,000 in the first half of 2011.

During the first half of 2011, the Company generated free cash flow of $26,929,000 compared to free cash flow of $45,971,000 in the first half of 2010. The slight decrease was primarily attributable to the same items as noted above which impacted operating cash flows. Free cash flow is a non-GAAP financial measure that is comprised of net cash provided by operating activities, excluding net cash impact related to restructuring activities, less purchases of property and equipment, net of proceeds from sales of property and equipment. Management believes that this financial measure provides meaningful information for evaluating the overall financial performance of the Company and its ability to repay debt or make future investments (including, for example, acquisitions). However, it should be noted that the Company’s definition of free cash flow may not be comparable to similar measures disclosed by other companies because not all companies calculate free cash flow in the same manner.

The non-GAAP financial measure is reconciled to the GAAP measure as follows (in thousands):

	Six Months Ended June 30,
	2011			2010
Net cash provided by operating activities	$	36,996		$	54,080
Less: Purchases of property and equipment - net		(10,067	)		(8,109	)
Free Cash Flow	$	26,929		$	45,971

DIVIDEND POLICY

On May 19, 2011, the Company’s Board of Directors declared a quarterly cash dividend of $0.0125 per Common Share to shareholders of record as of July 5, 2011, which was paid on July 15, 2011. At the current rate, the cash dividend will amount to $0.05 per Common Share on an annual basis.

CRITICAL ACCOUNTING POLICIES

The Consolidated Financial Statements included in the report include accounts of the Company and all majority-owned subsidiaries. The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions in certain circumstances that affect amounts reported in the accompanying Consolidated Financial Statements and related footnotes. In preparing the financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. However, application of these accounting policies involves the exercise of judgment and use of assumptions as to future uncertainties and, as a result, actual results could differ from these estimates.

The following critical accounting policies, among others, affect the more significant judgments and estimates used in preparation of the Company’s consolidated financial statements.

Revenue Recognition

Invacare’s revenues are recognized when products are shipped to unaffiliated customers. Revenue Recognition, ASC 605, provides guidance on the application of generally accepted accounting principles to selected revenue recognition issues. The Company has concluded that its revenue recognition policy is appropriate and in accordance with GAAP and ASC 605. Shipping and handling costs are included in cost of goods sold.

Sales are made only to customers with whom the Company believes collection is reasonably assured based upon a credit analysis, which may include obtaining a credit application, a signed security agreement, personal guarantee and/or a cross corporate guarantee depending on the credit history of the customer. Credit lines are established for new customers after an evaluation of their credit report and/or other relevant financial information. Existing credit lines are regularly reviewed and adjusted with consideration given to any outstanding past due amounts.

31

The Company offers discounts and rebates, which are accounted for as reductions to revenue in the period in which the sale is recognized. Discounts offered include: cash discounts for prompt payment, base and trade discounts based on contract level for specific classes of customers. Volume discounts and rebates are given based on large purchases and the achievement of certain sales volumes. Product returns are accounted for as a reduction to reported sales with estimates recorded for anticipated returns at the time of sale. The Company does not ship any goods on consignment.

Distributed products sold by the Company are accounted for in accordance with the revenue recognition guidance in ASC 605-45-05. The Company records distributed product sales gross as a principal since the Company takes title to the products and has the risks of loss for collections, delivery and returns.

Product sales that give rise to installment receivables are recorded at the time of sale when the risks and rewards of ownership are transferred. Interest income is recognized on installment agreements in accordance with the terms of the agreements. Installment accounts are monitored and if a customer defaults on payments, interest income is no longer recognized. All installment accounts are accounted for using the same methodology, regardless of duration of the installment agreements.

Allowance for Uncollectible Accounts Receivable

The estimated allowance for uncollectible amounts is based primarily on management’s evaluation of the financial condition of the customer. In addition, as a result of the third party financing arrangement, management monitors the collection status of these contracts in accordance with the Company’s limited recourse obligations and provides amounts necessary for estimated losses in the allowance for doubtful accounts and establishing reserves for specific customers as needed.

The Company continues to closely monitor the credit-worthiness of its customers and adhere to tight credit policies. During the first quarter of 2011, the Centers for Medicare and Medicaid Services implemented the single payment amounts for Round 1 of the Competitive Bidding Program in nine metropolitan statistical areas (MSAs). The single payment amounts are used to determine the price that Medicare pays for certain durable medical equipment, prosthetics, orthotics and supplies. The company believes the changes announced could have a significant impact on the collectability of accounts receivable for those customers which are in the MSA locations impacted and which have a portion of their revenues tied to Medicare reimbursement. As a result, this is an additional risk factor which the Company considers when assessing the collectability of accounts receivable.

Invacare has an agreement with DLL, a third party financing Company, to provide the majority of future lease financing to Invacare’s North America customers. The DLL agreement provides for direct leasing between DLL and the Invacare customer. The Company retains a recourse obligation for events of default under the contracts. The Company monitors the collections status of these contracts and has provided amounts for estimated losses in its allowances for doubtful accounts.

Inventories and Related Allowance for Obsolete and Excess Inventory

Inventories are stated at the lower of cost or market with cost determined by the first-in, first-out method. Inventories have been reduced by an allowance for excess and obsolete inventories. The estimated allowance is based on management’s review of inventories on hand compared to estimated future usage and sales. A provision for excess and obsolete inventory is recorded as needed based upon the discontinuation of products, redesigning of existing products, new product introductions, market changes and safety issues. Both raw materials and finished goods are reserved for on the balance sheet.

In general, Invacare reviews inventory turns as an indicator of obsolescence or slow moving product as well as the impact of new product introductions. Depending on the situation, the Company may partially or fully reserve for the individual item. The Company continues to increase its overseas sourcing efforts, increase its emphasis on the development and introduction of new products, and decrease the cycle time to bring new product offerings to market. These initiatives are sources of inventory obsolescence for both raw material and finished goods.

Goodwill, Intangible and Other Long-Lived Assets

Property, equipment, intangibles and certain other long-lived assets are amortized over their useful lives. Useful lives are based on management’s estimates of the period that the assets will generate revenue. Under Intangibles—Goodwill and Other, ASC 350, goodwill and intangible assets deemed to have indefinite lives are subject to annual impairment tests. Furthermore, goodwill and other long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company completes its annual impairment tests in the fourth quarter of each year. The discount rates used have a significant impact upon the discounted cash flow methodology utilized in the Company’s annual impairment testing as higher discount rates decrease the fair value estimates.

32

The Company utilizes a discounted cash flow method model to analyze reporting units for impairment in which the Company forecasts income statement and balance sheet amounts based on assumptions regarding future sales growth, profitability, inventory turns, days’ sales outstanding, etc. to forecast future cash flows. The cash flows are discounted using a weighted average cost of capital discount rate where the cost of debt is based on quoted rates for 20-year debt of companies of similar credit risk and the cost of equity is based upon the 20-year treasury rate for the risk free rate, a market risk premium, the industry average beta and a small cap stock adjustment. The assumptions used are based on a market participant’s point of view and yielded a discount rate of 9.59% in 2010 compared to 10.74% in 2009.

The Company also utilizes an EV (Enterprise Value) to EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) Method to compute the fair value of its reporting units which considers potential acquirers and their EV to EBITDA multiples adjusted by an estimated premium. While more weight is given to the discounted cash flow method, the EV to EBITDA Method does provide corroborative evidence of the reasonableness of the discounted cash flow method results.

While there was no indication of impairment in 2010 related to goodwill, a future potential impairment is possible for any of the Company’s reporting units should actual results differ materially from forecasted results used in the valuation analysis. Furthermore, the Company’s annual valuation of goodwill can differ materially if the market inputs used to determine the discount rate change significantly. For instance, higher interest rates or greater stock price volatility would increase the discount rate and thus increase the chance of impairment. For example, if the discount rate used were 100 basis points higher for the 2010 impairment analysis, there still would not be any indicator of potential impairment for any of the reporting units.

Product Liability

The Company’s captive insurance company, Invatection Insurance Co., currently has a policy year that runs from September 1 to August 31 and insures annual policy losses of $10,000,000 per occurrence and $13,000,000 in the aggregate of the Company’s North American product liability exposure. The Company also has additional layers of external insurance coverage insuring up to $75,000,000 in annual aggregate losses arising from individual claims anywhere in the world that exceed the captive insurance company policy limits or the limits of the Company’s per country foreign liability limits, as applicable. There can be no assurance that Invacare’s current insurance levels will continue to be adequate or available at affordable rates.

Product liability reserves are recorded for individual claims based upon historical experience, industry expertise and indications from the third-party actuary. Additional reserves, in excess of the specific individual case reserves, are provided for incurred but not reported claims based upon third-party actuarial valuations at the time such valuations are conducted. Historical claims experience and other assumptions are taken into consideration by the third-party actuary to estimate the ultimate reserves. For example, the actuarial analysis assumes that historical loss experience is an indicator of future experience, that the distribution of exposures by geographic area and nature of operations for ongoing operations is expected to be very similar to historical operations with no dramatic changes and that the government indices used to trend losses and exposures are appropriate.

Estimates made are adjusted on a regular basis and can be impacted by actual loss awards and settlements on claims. While actuarial analysis is used to help determine adequate reserves, the Company is responsible for the determination and recording of adequate reserves in accordance with accepted loss reserving standards and practices.

Warranty

Generally, the Company’s products are covered from the date of sale to the customer by warranties against defects in material and workmanship for various periods depending on the product. Certain components carry a lifetime warranty. A provision for estimated warranty cost is recorded at the time of sale based upon actual experience. The Company continuously assesses the adequacy of its product warranty accrual and makes adjustments as needed. Historical analysis is primarily used to determine the Company’s warranty reserves. Claims history is reviewed and provisions are adjusted as needed. However, the Company does consider other events, such as a product recall, which could warrant additional warranty reserve provision. No material adjustments to warranty reserves were necessary in the current year. See Warranty Costs in the Notes to the Condensed Consolidated Financial Statements included in this report for a reconciliation of the changes in the warranty accrual.

Accounting for Stock-Based Compensation

The Company accounts for share based compensation under the provisions of Compensation—Stock Compensation, ASC 718. The Company has not made any modifications to the terms of any previously granted options and no changes have been made regarding the valuation methodologies or assumptions used to determine the fair value of options granted since 2005 and the Company continues to use a Black-Scholes valuation model. As of June 30, 2011, there was $12,380,000 of total unrecognized compensation cost from stock-based compensation arrangements granted under the 2003 Plan, which is related to non-vested options and shares, and includes $3,920,000 related to restricted stock awards. The Company expects the compensation expense to be recognized over a four-year period for a weighted-average period of approximately two years.

33

The substantial majority of the options awarded have been granted at exercise prices equal to the market value of the underlying stock on the date of grant. Restricted stock awards granted without cost to the recipients are expensed on a straight-line basis over the vesting periods.

Income Taxes

As part of the process of preparing its financial statements, the Company is required to estimate income taxes in various jurisdictions. The process requires estimating the Company’s current tax exposure, including assessing the risks associated with tax audits, as well as estimating temporary differences due to the different treatment of items for tax and accounting policies. The temporary differences are reported as deferred tax assets and or liabilities. Substantially all of the Company’s U.S. deferred tax assets are offset by a valuation allowance. The Company also must estimate the likelihood that its deferred tax assets will be recovered from future taxable income and whether or not valuation allowances should be established. In the event that actual results differ from its estimates, the Company’s provision for income taxes could be materially impacted. The Company does not believe that there is a substantial likelihood that materially different amounts would be reported related to its critical accounting policies.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In June 2011, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2011-05, Presentation of Comprehensive Income (ASU 2011-05 or the ASU). ASU 2011-05 requires comprehensive income to be reported in either a single statement of in two consecutive statements reporting net income and other comprehensive income (OCI). The ASU does not change what is required to be reported in OCI or the requirement to disclose reclassifications of items from OCI to net income. The Company is analyzing the impact of ASU 2011-05, which is required to be adopted for the Company’s first quarter 2012 Form 10-Q. The Company does not believe ASU 2011-05 will have a material impact on the Company’s financial position, results of operations or cash flows.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company is exposed to market risk through various financial instruments, including fixed rate and floating rate debt instruments. The Company does at times use interest swap agreements to mitigate its exposure to interest rate fluctuations. Based on June 30, 2011 debt levels, a 1% change in interest rates would impact interest expense by approximately $1,465,000. Additionally, the Company operates internationally and, as a result, is exposed to foreign currency fluctuations. Specifically, the exposure results from intercompany loans, intercompany sales or payments and third party sales or payments. In an attempt to reduce this exposure, foreign currency forward contracts are utilized to hedge intercompany purchases and sales as well as third party purchases and sales. The Company does not believe that any potential loss related to these financial instruments would have a material adverse effect on the Company’s financial condition or results of operations.

The Company’s Credit Agreement provides for a $400,000,000 senior secured revolving credit facility maturing in October 2015 at variable rates. As of June 30, 2011, the Company had outstanding $31,387,000 in principal amount of 4.125% Convertible Senior Subordinated Debentures due in February 2027, of which $9,708,000 is included in equity. Accordingly, while the Company is exposed to increases in interest rates, its exposure to the volatility of the current market environment is limited as the Company does not currently need to re-finance any of its debt. However, the Company’s Credit Agreement contains covenants with respect to, among other items, consolidated funded indebtedness to consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) and interest coverage, as defined in the agreement. The Company is in compliance with all covenant requirements, but should it fall out of compliance with these requirements, the Company would have to attempt to obtain alternative financing and thus likely be required to pay much higher interest rates.

During the first six months of 2011, the Company entered into interest rate swap agreements to effectively convert a portion of floating rate revolving credit facility debt to fixed rate debt to avoid the risk of changes in market interest rates. Specifically, interest rate swap agreements for notional amounts of $18,000,000 through June 2013, $20,000,000 and $25,000,000 through May 2013 and $15,000,000 through February 2013 were entered into that fix the LIBOR component of the interest rate on that portion of the revolving credit facility debt at rates of 0.625%, 1.08%, 0.73% and 1.05%, respectively, for effective aggregate rates of 2.375%, 2.83%, 2.48% and 2.80%, respectively.

34

FORWARD-LOOKING STATEMENTS

This Form 10-Q contains forward-looking statements within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995. Terms such as “will,” “should,” “could”, “plan,” “intend,” “expect,” “continue,” “forecast,” “believe,” “anticipate” and “seek,” as well as similar comments, are forward-looking in nature. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Actual results and events may differ significantly from those expressed or anticipated as a result of risks and uncertainties which include, but are not limited to, the following: adverse changes in government and other third-party payor reimbursement levels and practices (such as, for example, the Medicare bidding program covering nine metropolitan areas beginning in 2011 and an additional 91 metropolitan areas beginning in 2013), impacts of the U.S. health care reform legislation that was recently enacted (such as, for example, the excise tax beginning in 2013 on certain medical devices, together with further regulations to be promulgated by the U.S. Secretary of Treasury, if adopted); legal actions, regulatory proceedings or governmental investigations (including, for example, compliance costs or other adverse effects of enforcement actions which could arise from the current, ongoing FDA investigations); product liability claims; extensive government regulation of the Company’s products; failure to comply with regulatory requirements or receive regulatory clearance or approval for the Company’s products or operations in the United States or abroad; the uncertain impact on the Company’s providers, on the Company’s suppliers and on the demand for the Company’s products resulting from the current global economic conditions and general volatility in the credit and stock markets; loss of key health care providers; exchange rate and tax rate fluctuations; inability to design, manufacture, distribute and achieve market acceptance of new products with higher functionality and lower costs; consolidation of health care providers and the Company’s competitors; lower cost imports; uncollectible accounts receivable; difficulties in implementing/upgrading Enterprise Resource Planning systems; risks inherent in managing and operating businesses in many different foreign jurisdictions; ineffective cost reduction and restructuring efforts; potential product recalls; natural disasters that lead to supply chain disruptions beyond the Company’s control; possible adverse effects of being leveraged, which could impact the Company’s ability to raise capital, limit its ability to react to changes in the economy or the health care industry or expose the Company to interest rate or event of default risks; increased freight costs; inadequate patents or other intellectual property protection; incorrect assumptions concerning demographic trends that impact the market for the Company’s products; unanticipated changes in the Company’s product sales mix; decreased availability or increased costs of materials which could increase the Company’s costs of producing or acquiring the Company’s products, including possible increases in commodity costs; the loss of the services of or inability to attract and maintain the Company’s key management and personnel; inability to acquire strategic acquisition candidates because of limited financing alternatives; increased security concerns and potential business interruption risks associated with political and/or social unrest in foreign countries where the Company’s facilities or assets are located; provisions of Ohio law or in the Company’s debt agreements, shareholder rights plan or charter documents that may prevent or delay a change in control, as well as the risks described from time to time in Invacare’s reports as filed with the Securities and Exchange Commission. Except to the extent required by law, we do not undertake and specifically decline any obligation to review or update any forward-looking statements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments or otherwise.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

The information called for by this item is provided under the same caption under Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Item 4. Controls and Procedures.

As of June 30, 2011, an evaluation was performed, under the supervision and with the participation of the Company’s management, including the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)). Based on that evaluation, the Company’s management, including the Chief Executive Officer and Chief Financial Officer, concluded that the Company’s disclosure controls and procedures were effective, as of June 30, 2011, in ensuring that information required to be disclosed by the Company in the reports it files and submits under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the Commission’s rules and forms and (2) accumulated and communicated to the Company’s management, including the Chief Executive Officer and the Chief Financial Officer, as appropriate to allow for timely decisions regarding required disclosure. There were no changes in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

35

Part II. OTHER INFORMATION

Item 1. Legal Proceedings.

The Company continues to work on the improvements and corrective actions that it is making in response to regulatory compliance concerns raised by the FDA, including as a result of the FDA warning letter that was previously disclosed by the Company. The Company is in the process of adding resources to its regulatory affairs and corporate compliance departments and is engaging outside experts to accelerate implementation of various corrective actions. At the time of this filing, the matter remains pending and the Company continues to view its regulatory compliance actions as a high priority.

Item 1A. Risk Factors.

In addition to the other information set forth in this report, you should carefully consider the risk factors disclosed in Item 1A of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

  (c) The following table presents information with respect to repurchases of common shares made by the Company during the three months ended June 30, 2011.

Period	Total Number of Shares  Purchased (1)		Average Price Paid Per  Share		Total Number of  Shares Purchased as Part of Publicly Announced Plans or Programs		Maximum Number of Shares  That May Yet Be Purchased Under the Plans or Programs (2)
4/1/2011-4/30/11		0	$	0.00		0		665,400
5/1/2011-5/31/11		8,833		32.30		8,200		657,200
6/1/2011-6/30/11		40,200		32.43		40,200		617,000
Total		49,033	$	32.41		48,400		617,000

(1) Includes 633 shares repurchased between May 1, 2011 and May 31, 2011 that were surrendered to the Company by employees for tax withholding purposes in conjunction with the vesting of restricted shares held by the employees under the company’s 2003 Performance Plan.

(2) On August 17, 2001, the Board of Directors authorized the Company to purchase up to 2,000,000 Common Shares, excluding any shares acquired from employees or directors as a result of the exercise of options or vesting of restricted shares pursuant to the Company’s performance plans. The Board of Directors reaffirmed its authorization of this repurchase program on November 5, 2010. As of June 30, 2011, the Company has purchased 1,383,000 shares with authorization remaining to purchase 617,000 more shares. The Company purchased 540,900 shares pursuant to this Board authorized program during the first six months of 2011.

During the first half of 2011, the Company purchased a total of $45,814,000 in principal amount of its outstanding 4.125% Convertible Senior Subordinated Debentures due 2027 in open market transactions for an aggregate purchase price of approximately $63,798,000, plus accrued and unpaid interest. The Company may continue from time to time seek to retire or purchase the Company’s outstanding 4.125% Convertible Senior Subordinated Debentures due 2027, in open market purchases, privately negotiated transactions or otherwise.

Item 6. Exhibits.

Exhibit       No.
10.1	Form of Indemnity Agreement entered into by and between the Company and its directors and certain of its executive officers and schedule of all such agreements with directors and executive officers.
31.1	Chief Executive Officer Rule 13a-14(a)/15d-14(a) Certification (filed herewith).
31.2	Chief Financial Officer Rule 13a-14(a)/15d-14(a) Certification (filed herewith).
32.1	Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).
32.2	Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).
101	The following materials from Invacare Corporation’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2011, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Statements of Earnings for the three and six months ended June 30, 2011 and 2010, (ii) Condensed Consolidated Balance Sheets as of June 30, 2011 and December 31, 2010, (iii) Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2011 and 2010, and (iv) Notes to Condensed Consolidated Financial Statements.**

** Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

36

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	INVACARE CORPORATION
Date:  August 8, 2011	By:	/s/ Robert K. Gudbranson
		Name:  Robert K. Gudbranson
		Title:  Chief Financial Officer
		(As Principal Financial and Accounting Officer and on behalf of the registrant)

37

EX-10.1

Exhibit 10.1

INVACARE CORPORATION

FORM OF INDEMNITY AGREEMENT

THIS AGREEMENT is made as of the      day of         , 20    , by and between INVACARE CORPORATION, an Ohio corporation (the “Corporation”), and              (“Indemnitee”), a Director and an Officer of the Corporation.

WHEREAS, it is essential to the Corporation to retain and attract as Directors and/or Officers the most capable persons available, such as Indemnitee; and

WHEREAS, the prevalence of corporate litigation subjects directors and officers to expensive litigation risks, and it is the policy of the Corporation to indemnify its Directors and/or Officers so as to provide them with the maximum possible protection permitted by law; and

WHEREAS, in addition, because the statutory indemnification provisions of the Ohio Revised Code expressly provide that they are non-exclusive, it is the policy of the Corporation to indemnify Directors and Officers who, on behalf of the Corporation, have entered into settlements of derivative suits or have paid judgments, fines or penalties therefor, provided they have not breached the applicable statutory standard of conduct; and

WHEREAS, Indemnitee does not regard the protection available under the Corporation’s Code of Regulations and insurance, if any, as adequate in the present circumstances, and considers it necessary and desirable to his or her service as a Director and/or Officer to have maximum protection, and the Corporation desires to provide such protection to induce Indemnitee to serve in such capacity; and

WHEREAS, the Ohio Revised Code Section 1701.13(E) and the Corporation’s Code of Regulations Article V(a) provide that indemnification of Directors and Officers of the Corporation may be authorized by agreement, and thereby contemplates that contracts of this nature may be entered into between the Corporation and Indemnitee with respect to indemnification of Indemnitee as a Director or an Officer of the Corporation.

NOW, THEREFORE, for good and valuable consideration, the sufficiency and adequacy of which is hereby acknowledged, the Corporation and Indemnitee do hereby agree as follows:

1. Agreement to Serve. Indemnitee agrees to serve or continue to serve as a Director and/or Officer of the Corporation for so long as he or she is duly elected or appointed or until such time as he or she tenders his or her resignation in writing or is otherwise terminated or removed from office.

The Corporation expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on the Corporation hereby in order to induce Indemnitee to continue to serve as a Director and/or Officer of the Corporation, and acknowledges that Indemnitee is relying upon this Agreement in continuing in such capacity.

2. Definitions. As used in this Agreement:

The term “Proceeding” shall include any threatened, pending, or completed action, suit or proceeding, whether brought by or in the right of the Corporation or otherwise and whether of a civil, criminal, administrative or investigative nature, in which Indemnitee may be or may have been involved as a party or otherwise, by reason of the fact that Indemnitee is or was a Director and/or Officer of the Corporation or any subsidiary of the Corporation, by reason of any action taken by Indemnitee or of any inaction on his or her part while acting as such a Director and/or Officer, or by reason of the fact that he or she is or was serving at the request of the Corporation as a director, officer, member or manager, partner, trustee, employee or agent of another corporation, domestic or foreign, non-profit or for-profit, a limited liability company or a partnership, joint venture, trust or other enterprise; in each case whether or not he or she is acting or serving in any such capacity at the time any liability or expense is incurred for which indemnification or reimbursement can be provided under this Agreement.

The term “Expenses” shall include, without limitation, expenses of investigations, judicial or administrative proceedings or appeals, attorneys’ fees and disbursements and any expenses of establishing a right to indemnification under Paragraph 9 of this Agreement, but shall not include the amount of judgments, fines or penalties against or settlements paid by Indemnitee.

References to “other enterprise” shall include, without limitation, employee benefit plans; references to “fines” shall include, without limitation, any excise tax assessed with respect to any employee benefit plan; references to “serving at the request of the Corporation” shall include, without limitation, any service as a Director or Officer of the Corporation which imposes duties on, or involves services by, such Director or Officer with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner he or she reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interests of the Corporation” as referred to in this Agreement.

3. Indemnity in Third-Party Proceedings. The Corporation shall indemnify Indemnitee in accordance with the provisions of this Paragraph 3 if Indemnitee is a party to or threatened to be made a party to or otherwise involved in any Proceeding (other than a Proceeding by or in the right of the Corporation to procure a judgment in its favor) by reason of the fact that Indemnitee is or was a Director and/or Officer of the Corporation or a subsidiary of the Corporation, or is or was serving at the request of the Corporation as a director, officer, member or manager, partner, trustee, employee or agent of another corporation, domestic or foreign, non-profit or for-profit, a limited liability company or a partnership, joint venture, trust or other enterprise, against all Expenses, judgments, settlements, fines and penalties, actually and reasonably incurred by Indemnitee in connection with the defense or settlement of such Proceeding, but only if Indemnitee acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Corporation and, in the case of a criminal proceeding, had no reasonable cause to believe that his or her conduct was unlawful. The termination of any such Proceeding by judgment, order of court, settlement, conviction or upon a plea of nolo contendere, or its equivalent, shall not, of itself, create a presumption that Indemnitee did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Corporation, and with respect to any criminal proceeding, that such person had reasonable cause to believe that his or her conduct was unlawful.

4. Indemnity for Expenses in Proceedings by or in the Right of the Corporation. The Corporation shall indemnify Indemnitee in accordance with the provisions of this Paragraph 4 if Indemnitee is a party to or threatened to be made a party to any Proceeding by or in the right of the Corporation to procure a judgment in its favor by reason of the fact that Indemnitee is or was a Director and/or Officer of the Corporation or a subsidiary of the Corporation, or is or was serving at the request of the Corporation as a director, officer, member or manager, partner, trustee, employee or agent of another corporation, domestic or foreign, non-profit or for-profit, a limited liability company or a partnership, joint venture, trust or other enterprise, against all Expenses actually and reasonably incurred by Indemnitee in connection with the defense of such Proceeding, but only if he or she acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Corporation, except that no indemnification for Expenses shall be made under this Paragraph 4 in respect of any claim, issue or matter as to which Indemnitee shall have been adjudged by a court order or judgment, by a court of competent jurisdiction, to be liable to the Corporation, unless and only to the extent that any court in which such Proceeding was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnity for such expenses as such court shall deem proper.

5. Indemnity for Amounts Paid in Settlement in Proceedings by or in the Right of the Corporation. The Corporation shall indemnify Indemnitee in accordance with the provisions of this Paragraph 5 if Indemnitee is a party to or threatened to be made a party to any Proceeding by or in the right of the Corporation to procure a judgment in its favor by reason of the fact that Indemnitee is or was a Director and/or Officer of the Corporation or a subsidiary of the Corporation, or is or was serving at the request of the Corporation as a director, officer, member or manager, partner, trustee, officer, employee, or agent of another corporation, domestic or foreign, non-profit or for-profit, a limited liability company or a partnership, joint venture, trust or other enterprise, against all amounts actually and reasonably paid in settlement by Indemnitee in connection with any such Proceeding, but only if he or

she acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Corporation.

6. Indemnity for Amounts Paid for in Judgments in Proceedings by or in the Right of the Corporation. The Corporation shall indemnify Indemnitee in accordance with the provisions of this Paragraph 6 if Indemnitee is a party to or threatened to be made a party to any Proceeding by or in the right of the Corporation to procure a judgment in its favor by reason of the fact that Indemnitee is or was a Director and/or Officer of the Corporation or a subsidiary of the Corporation, or is or was serving at the request of the Corporation as a director, officer, member or manager, partner, trustee, officer, employee, or agent of another corporation, domestic or foreign, non-profit or for-profit, a limited liability company or a partnership, joint venture, trust or other enterprise, against all judgments, fines and penalties actually and reasonably incurred by Indemnitee in connection with any such Proceeding, but only if he or she acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Corporation.

7. Indemnification of Expenses of Successful Party. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee has been successful on the merits or otherwise in defense of any Proceeding or in defense of any claim, issue or matter therein, including dismissal without prejudice, Indemnitee shall be indemnified against all Expenses incurred in connection therewith.

8. Advances of Expenses. Any Expenses incurred by or on behalf of Indemnitee pursuant to Paragraphs 3 or 4 in any Proceeding shall be paid by the Corporation in advance upon the written request of Indemnitee if Indemnitee shall undertake to (a) repay such amount to the extent that it is ultimately determined by clear and convincing evidence in a court that Indemnitee is not entitled to indemnification hereunder, and (b) reasonably cooperate with the Corporation concerning the action, suit or proceeding giving rise to the Expenses. Any advances to be made under this Paragraph 8 shall be paid by the Corporation to Indemnitee within twenty (20) days following delivery of a written request therefor by Indemnitee to the Corporation.

9. Procedure. Any indemnification and advances provided for in Paragraph 3, 4, 5, 6, 7 and 8 shall be made no later than twenty (20) days after receipt of the written request of Indemnitee. If a claim under this Agreement, under any statute, or under any provision of the Corporation’s Code of Regulations or Articles of Incorporation providing for indemnification, is not paid in full by the Corporation within twenty (20) days after a written request for payment thereof has been first received by the Corporation, Indemnitee may, but need not, at any time thereafter bring an action against the Corporation to recover the unpaid amount of the claim and, subject to the other provisions of this Agreement, Indemnitee also shall be entitled to be paid for the Expenses of bringing such action. It shall be a defense to any such action (other than an action brought to enforce a claim for Expenses incurred in connection with any action, suit or proceeding in advance of its final disposition) that Indemnitee has not met the standards of conduct which make it permissible under applicable law for the Corporation to indemnify Indemnitee for the amount claimed, but the burden of proving such defense shall be on the Corporation and Indemnitee shall be entitled to receive advance payments of expenses pursuant to Paragraph 8 hereof unless and until such defense may be finally adjudicated by court order or judgment from which no further right of appeal exists. It is the parties’ intention that if the Corporation contests Indemnitee’s right to indemnification, the question of Indemnitee’s right to indemnification shall be for the court to decide. There shall exist in such action a rebuttable presumption that Indemnitee has met the applicable standard(s) of conduct and is therefore entitled to indemnification pursuant to this Agreement. Neither the failure of the Corporation (including its Board of Directors, any committee or subgroup of the Board of Directors, independent legal counsel or its shareholders) to have made a determination that indemnification of Indemnitee is proper in the circumstances because Indemnitee has met the applicable standard of conduct as may be required by applicable law, nor any actual determination by the Corporation (including its Board of Directors, any committee or subgroup of the Board of Directors, independent legal counsel, or its shareholders) that Indemnitee has not met such applicable standard of conduct, shall (a) constitute a defense to such action, (b) create a presumption that Indemnitee has or has not met the applicable standard of conduct, or (c) otherwise alter the presumption in favor of Indemnitee referred to in the preceding sentence.

10. Allowance for Compliance with SEC Requirements. Indemnitee acknowledges that the Securities and Exchange Commission (“SEC”) has expressed the opinion that indemnification of directors and officers from liabilities under the Securities Act of 1933, as amended (the “Act”), is against public policy as expressed in the Act

and is, therefore, unenforceable. Indemnitee hereby acknowledges and agrees that it will not be a breach of this Agreement for the Corporation to undertake with the SEC in connection with the registration for sale of any capital stock or other securities of the Corporation from time to time that, in the event a claim for indemnification against such liabilities (other than the payment by the Corporation of expenses incurred or paid by a director or officer of the Corporation in the successful defense of any action, suit or proceeding) is asserted in connection with such capital stock or other securities being registered, the Corporation will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of competent jurisdiction on the question of whether or not such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. Indemnitee further agrees that such submission to a court of competent jurisdiction shall not be a breach of this Agreement.

11. Indemnification Hereunder Not Exclusive. The indemnification provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may be entitled under the Articles of Incorporation or the Code of Regulations of the Corporation, any agreement, any vote of shareholders or disinterested directors, the Ohio General Corporation Laws, or otherwise, both as to action in his or her official capacity and as to action in another capacity while holding such office.

The indemnification under this Agreement for any action taken or not taken while serving in an indemnified capacity shall continue as to Indemnitee even though he or she may have ceased to be a Director and/or Officer and shall inure to the benefit of the heirs, executors and personal representatives of Indemnitee.

12. Partial Indemnification. If Indemnitee is entitled under any provision of this Agreement to indemnification by the Corporation for some claims, issues or matters, but not as to other claims, issues or matters, or for some or a portion of the Expenses, judgments, fines or penalties actually and reasonably incurred by Indemnitee or amounts actually and reasonably paid in settlement by Indemnitee in the investigation, defense, appeal or settlement of any Proceeding, but not for the total amount thereof, the Corporation shall nevertheless indemnify Indemnitee for the portion of such claims, issues or matters or Expenses, judgments, fines, penalties or amounts paid in settlement to which Indemnitee is entitled.

13. No Rights of Continued Employment. Nothing contained in this Agreement is intended to create in Indemnitee any right to continued employment with the Corporation.

14. Reimbursement to Corporation by Indemnitee; Limitation on Amounts Paid by Corporation. To the extent Indemnitee has been indemnified by the Corporation hereunder and later receives payments from any insurance carrier covering the same Expenses, judgments, fines, penalties or amounts paid in settlement so indemnified by the Corporation hereunder, Indemnitee shall immediately reimburse the Corporation hereunder for all such amounts received from the insurer.

Notwithstanding anything contained herein to the contrary, Indemnitee shall not be entitled to recover amounts under this Agreement which, when added to the amount of indemnification payments made to, or on behalf of, Indemnitee, under the Articles of Incorporation or Code of Regulations of the Corporation, in the aggregate exceed the Expenses, judgments, fines, penalties and amounts paid in settlement actually and reasonably incurred by Indemnitee (“Excess Amounts”). To the extent the Corporation has paid Excess Amounts to Indemnitee, Indemnitee shall be obligated to immediately reimburse the Corporation for such Excess Amounts.

Notwithstanding anything contained herein to the contrary, the Corporation shall not be obligated under the terms of this Agreement to indemnify Indemnitee:

(a) or advance expenses to Indemnitee with respect to proceedings or claims initiated or brought voluntarily by Indemnitee and not by way of defense, except with respect to Proceedings brought to establish or enforce a right to indemnification under this Agreement or any other statute or law or otherwise, but such indemnification or advancement of expenses may be provided by the Corporation in specific cases if the Board of Directors finds it appropriate;

(b) if it is proved by final judgment in a court of law or other final adjudication to have been based upon or attributable to the Indemnitee’s in fact having gained any personal profit or advantage to which he or she was not legally entitled;

(c) for any expenses incurred by Indemnitee with respect to any proceeding instituted by Indemnitee to enforce or interpret this Agreement, if a court of competent jurisdiction determines that each of the material assertions made by Indemnitee in such proceeding was not made in good faith or was frivolous;

(d) for a disgorgement of profits made from the purchase and sale by Indemnitee of securities pursuant to Section 16(b) of the Securities Exchange Act of 1934, as amended, or similar provisions of any state statutory law or common law; or

(e) for any Expenses, judgment, fine or penalty which the Corporation is prohibited by applicable law from paying as indemnity or for any other reason.

15. Scope. Notwithstanding any other provision of this Agreement, except Paragraph 14 hereof, the Corporation hereby agrees to indemnify the Indemnitee to the fullest extent permitted by law, notwithstanding that such indemnification is not specifically authorized by the other provisions of this Agreement, the Corporation’s Code of Regulations or Articles of Incorporation, or by statute. In the event of any change, after the date of this Agreement, in any applicable law, statute or rule which expands the right of an Ohio corporation to indemnify a member of its board of directors or an officer, such change shall be deemed to be within the purview of the Indemnitee’s rights and the Corporation’s obligations under this Agreement. In the event of any change in any applicable law, statute or rule which narrows the right of an Ohio corporation to indemnify a member of its board of directors or an officer, such change, to the extent not otherwise required by such law, statute or rule to be applied to this Agreement, shall have no effect on this Agreement or the parties’ rights and obligations hereunder.

16. Notice to Insurers. If, at the time of the receipt of a written request of Indemnitee pursuant to Paragraph 9 hereof, the Corporation has director and officer liability insurance in effect, the Corporation shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Corporation shall thereafter take all necessary or desirable action, using commercially reasonable efforts, to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies.

17. Continuation of Rights and Obligations. All rights and obligations of the Corporation and Indemnitee hereunder shall continue in full force and effect despite the subsequent amendment or modification of the Corporation’s Articles of Incorporation or Code of Regulations, as such are in effect on the date hereof, and such rights and obligations shall not be affected by any such amendment or modification, any resolution of directors or shareholders of the Corporation, or by any other corporate action which conflicts with or purports to amend, modify, limit or eliminate any of the rights or obligations of the Corporation and/or Indemnitee hereunder.

18. Amendment and Modification. This Agreement may only be amended, modified or supplemented by the written agreement of the Corporation and Indemnitee.

19. Assignment. This Agreement shall not be assigned by the Corporation or Indemnitee without the prior written consent of the other party thereto, except that the Corporation may freely assign its rights and obligations under this Agreement to any subsidiary for whom Indemnitee is serving as a director and/or officer thereof; provided, however, that no permitted assignment shall release the assignor from its obligations hereunder. Subject to the foregoing, this Agreement and all of the provisions hereof shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns, including, without limitation, any successor to the Corporation by way of merger, consolidation and/or sale or disposition of all or substantially all of the capital stock of the Corporation.

20. Saving Clause. If this Agreement or any portion thereof shall be invalidated on any ground by any court of competent jurisdiction, the Corporation shall nevertheless indemnify Indemnitee as to Expenses, judgments, fines, penalties and amounts paid in settlement with respect to any Proceeding to the full extent permitted by any applicable portion of this Agreement that shall not have been invalidated or by any other applicable law.

21. Counterparts. This Agreement may be executed in two or more fully or partially executed counterparts each of which shall be deemed an original binding the signer thereof against the other signing parties, but all counterparts together shall constitute one and the same instrument. Executed signature pages may be removed from counterpart agreements and attached to one or more fully executed copies of this Agreement. The parties may execute and deliver this Agreement by facsimile signature, which shall have the same binding effect as an original ink signature.

22. Notice. Indemnitee shall, as a condition precedent to his or her right to be indemnified under this Agreement, give to the Corporation notice in writing as soon as practicable of any claim made against him or her for which indemnity will or could be sought under this Agreement. Notice to the Corporation shall be directed to the Corporation at its headquarters located at One Invacare Way, Elyria, Ohio 44035, Attention: Chairman (or such other address as the Corporation shall designate in writing to Indemnitee). Notice shall be deemed received three days after the date postmarked if sent by prepaid mail, properly addressed. In addition, Indemnitee shall give the Corporation such information and cooperation as it may reasonably require within Indemnitee’s power.

23. Applicable Law. All matters with respect to this Agreement, including, without limitation, matters of validity, construction, effect and performance, shall be governed by and construed in accordance with the laws of the State of Ohio applicable to contracts made and to be performed therein between the residents thereof (regardless of the laws that might otherwise be applicable under principles of conflict of law).

IN WITNESS WHEREOF, the parties hereby have caused this Agreement to be duly executed and signed as of the day and year first above written.

INVACARE CORPORATION

THE “CORPORATION”

By

Its:

“INDEMNITEE”

Schedule of Indemnity Agreements with Current Directors and Executive Officers

Person	Position	Date of Agreement
A. Malachi Mixon, III	Chairman of the Board and Director	May 24, 2001
Gerald B. Blouch	President & Chief Executive Officer and Director	May 24, 2001
Joseph B. Richey, II	President - Invacare Technologies, Senior Vice President - Electronics and Design Engineering and Director	May 24, 2001
Louis F.J. Slangen	Senior Vice President - Corporate Marketing and Chief Product Officer	May 24, 2001
Robert K. Gudbranson	Senior Vice President and Chief Financial Officer	April 1, 2008
Anthony C. LaPlaca	Senior Vice President and General Counsel	December 29, 2008
Patricia A. Stumpp	Senior Vice President - Human Resources	September 1, 2009
Carl E. Will	Senior Vice President - Global Commercial Operations	November 19, 2010
James C. Boland	Director	May 24, 2001
Michael F. Delaney	Director	May 24, 2001
Dan T. Moore, III	Director	May 24, 2001
William M. Weber	Director	May 24, 2001
Dr. C. Martin Harris	Director	January 24, 2003

Dale C. LaPorte	Director	February 12, 2009
Charles S. Robb	Director	March 1, 2010
James L. Jones	Director	December 1, 2010
Baiju R. Shah	Director	May 19, 2011

EX-31.1

Exhibit 31.1

CERTIFICATIONS

I, Gerald B. Blouch, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Invacare Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	Invacare Corporation
Date: August 8, 2011	By:	/s/ Gerald B. Blouch
		Name: Gerald B. Blouch
		Title: Chief Executive Officer (Principal Executive Officer)

EX-31.2

Exhibit 31.2

CERTIFICATIONS

I, Robert K. Gudbranson, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Invacare Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	Invacare Corporation
Date: August 8, 2011	By:	/s/ Robert K. Gudbranson
		Name: Robert K. Gudbranson
		Title: Chief Financial Officer (Principal Financial and Accounting Officer)

EX-32.1

Exhibit 32.1

Certification

Pursuant to Section 18 U.S.C. Section 1350,

as adopted pursuant to Section 906

of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Invacare Corporation (the “company”) on Form 10-Q for the period ending June 30, 2011 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Gerald B. Blouch, Chief Executive Officer of the company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the company.

	Invacare Corporation
Date: August 8, 2011	By:	/s/ Gerald B. Blouch
		Name: Gerald B. Blouch
		Title: Chief Executive Officer

A signed original of this written statement required by Section 906 has been provided to Invacare Corporation and will be retained by Invacare Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2

Exhibit 32.2

Certification

Pursuant to Section 18 U.S.C. Section 1350,

as adopted pursuant to Section 906

of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Invacare Corporation (the “company”) on Form 10-Q for the period ending June 30, 2011 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Robert K.Gudbranson, Chief Financial Officer of the company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the company.

	Invacare Corporation
Date: August 8, 2011	By:	/s/ Robert K. Gudbranson
		Name: Robert K. Gudbranson
		Title: Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to Invacare Corporation and will be retained by Invacare Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

XML



Condensed Consolidated Statement of Earnings (USD $) In Thousands, except Per Share data	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Condensed Consolidated Statement of Earnings
Net sales	$ 466,412	$ 430,828	$ 894,910	$ 833,068
Cost of products sold	331,494	304,338	636,986	588,865
Gross profit	134,918	126,490	257,924	244,203
Selling, general and administrative expense	112,417	104,421	218,194	206,197
Loss on debt extinguishment including debt finance charges and associated fees	11,855	14,048	16,736	18,434
Charge related to restructuring activities	431	0	431	0
Interest expense	2,233	5,770	4,844	12,162
Interest income	(279)	(163)	(546)	(310)
Earnings before income taxes	8,261	2,414	18,265	7,720
Income taxes (benefit)	(2,400)	3,025	150	5,225
NET EARNINGS (LOSS)	$ 10,661	$ (611)	$ 18,115	$ 2,495
DIVIDENDS DECLARED PER COMMON SHARE	$ 0.0125	$ 0.0125	$ 0.0250	$ 0.0250
Net earnings (loss) per share - basic	$ 0.33	$ (0.02)	$ 0.56	$ 0.08
Weighted average shares outstanding - basic	31,950	32,386	32,062	32,367
Net earnings (loss) per share - assuming dilution	$ 0.32	$ (0.02)	$ 0.55	$ 0.08
Weighted average shares outstanding - assuming dilution	33,006	32,386	33,026	32,669

XML



Condensed Consolidated Statement of Cash Flows (USD $) In Thousands	6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010
OPERATING ACTIVITIES
Net earnings	$ 18,115	$ 2,495
Adjustments to reconcile net earnings to net cash provided by operating activities:
Amortization of convertible debt discount	1,136	1,706
Loss on debt extinguishment including debt finance charges and associated fees	16,736	18,434
Depreciation and amortization	18,133	18,245
Provision for losses on trade and installment receivables	7,360	8,112
Provision for other deferred liabilities	1,508	1,421
Provision (benefit) for deferred income taxes	(628)	(117)
Provision for stock-based compensation	2,878	2,840
Gain (loss) on disposals of property and equipment	151	9
Changes in operating assets and liabilities:
Trade receivables	(15,359)	(5,132)
Installment sales contracts, net	(2,344)	(466)
Inventories	(6,921)	(9,807)
Other current assets	(4,855)	6,916
Accounts payable	12,356	13,780
Accrued expenses	(12,942)	(6,499)
Other deferred liabilities	1,672	2,143
NET CASH PROVIDED BY OPERATING ACTIVITIES	36,996	54,080
INVESTING ACTIVITIES
Purchases of property and equipment	(10,104)	(8,422)
Proceeds from sale of property and equipment	37	313
Other long term assets	(1,011)	813
Business acquisitions, net of cash acquired	0	(13,725)
Other	(76)	(223)
NET CASH USED FOR INVESTING ACTIVITIES	(11,154)	(21,244)
FINANCING ACTIVITIES
Proceeds from revolving lines of credit and long-term borrowings	230,752	201,661
Payments on revolving lines of credit and long-term debt and capital lease obligations	(237,881)	(219,847)
Proceeds from exercise of stock options	4,101	1,002
Payment of financing costs	(18,116)	(16,549)
Payment of dividends	(794)	(808)
Purchase of treasury stock	(16,213)	0
NET CASH USED BY FINANCING ACTIVITIES	(38,151)	(34,541)
Effect of exchange rate changes on cash	2,009	(4,591)
Decrease in cash and cash equivalents	(10,300)	(6,296)
Cash and cash equivalents at beginning of period	48,462	37,501
Cash and cash equivalents at end of period	$ 38,162	$ 31,205

XML



Supplemental Guarantor Information

6 Months Ended

Jun. 30, 2011

Supplemental Guarantor Information

Supplemental Guarantor Information

Supplemental Guarantor Information - Effective February 12, 2007, substantially all of the domestic subsidiaries (the "Guarantor Subsidiaries") of the Company became guarantors of the indebtedness of Invacare Corporation under its 4.125% Senior Subordinated Debentures due 2027 (the "Convertible Notes") with an initial aggregate principal amount of $135,000,000. The majority of the Company's subsidiaries, which are primarily foreign subsidiaries of the Company, are not guaranteeing the repayment of the Convertible Notes (the "Non-Guarantor Subsidiaries"). Each of the Guarantor Subsidiaries has fully and unconditionally guaranteed, on a joint and several basis, to pay principal, premium, and interest related to the Convertible Notes and each of the Guarantor Subsidiaries are directly or indirectly wholly-owned subsidiaries of the Company.

Presented below are the consolidating condensed financial statements of Invacare Corporation (Parent), its combined Guarantor Subsidiaries and combined Non-Guarantor Subsidiaries with their investments in subsidiaries accounted for using the equity method. The Company does not believe that separate financial statements of the Guarantor Subsidiaries are material to investors and accordingly, separate financial statements and other disclosures related to the Guarantor Subsidiaries are not presented.

CONSOLIDATING CONDENSED STATEMENTS OF OPERATIONS

(in thousands) Three month period ended June 30, 2011	The Company     (Parent)			Combined Guarantor   Subsidiaries		Combined Non-Guarantor   Subsidiaries			Eliminations			Total
Net sales	$	97,746		$	195,578	$	198,509		$	(25,421	)	$	466,412
Cost of products sold		71,276			151,004		134,329			(25,115	)		331,494
Gross Profit		26,470			44,574		64,180			(306	)		134,918
Selling, general and administrative expenses		36,451			15,924		49,299			10,743			112,417
Loss on debt extinguishment including debt finance charges and associated fees		11,855			0		0			0			11,855
Charges related to restructuring activities		0			0		431			0			431
Income (loss) from equity investee		33,627			13,727		1,078			(48,432	)		0
Interest expense - net		650			404		900			0			1,954
Earnings (loss) before Income Taxes		11,141			41,973		14,628			(59,481	)		8,261
Income taxes		480			100		(2,980	)		0			(2,400	)
Net Earnings (loss)	$	10,661		$	41,873	$	17,608		$	(59,481	)	$	10,661
Three month period ended June 30, 2010
Net sales	$	101,403		$	184,190	$	171,337		$	(26,102	)	$	430,828
Cost of products sold		72,635			143,762		113,978			(26,037	)		304,338
Gross Profit		28,768			40,428		57,359			(65	)		126,490
Selling, general and administrative expenses		35,501			28,367		40,553			0			104,421
Loss on debt extinguishment including debt finance charges and associated fees		14,048			0		0			0			14,048
Income (loss) from equity investee		25,203			7,239		(395	)		(32,047	)		0
Interest expense - net		4,703			202		702			0			5,607
Earnings (loss) before Income Taxes		(281	)		19,098		15,709			(32,112	)		2,414
Income taxes		330			403		2,292			0			3,025
Net Earnings (loss)	$	(611	)	$	18,695	$	13,417		$	(32,112	)	$	(611	)

CONSOLIDATING CONDENSED STATEMENTS OF OPERATIONS

(in thousands) Six month period ended June 30, 2011	The     Company     (Parent)		Combined Guarantor   Subsidiaries		Combined Non- Guarantor Subsidiaries			Eliminations			Total
Net sales	$	189,978	$	385,204	$	369,323		$	(49,595	)	$	894,910
Cost of products sold		137,614		300,055		248,690			(49,373	)		636,986
Gross Profit		52,364		85,149		120,633			(222	)		257,924
Selling, general and administrative expenses		69,151		30,117		94,809			24,117			218,194
Loss on debt extinguishment including debt finance charges and associated fees		16,736		0		0			0			16,736
Charges related to restructuring activities		0		0		431			0			431
Income (loss) from equity investee		54,451		18,061		1,056			(73,568	)		0
Interest expense - net		1,713		781		1,804			0			4,298
Earnings (loss) before Income Taxes		19,215		72,312		24,645			(97,907	)		18,265
Income taxes		1,100		200		(1,150	)		0			150
Net Earnings (loss)	$	18,115	$	72,112	$	25,795		$	(97,907	)	$	18,115
Six month period ended June 30, 2010
Net sales	$	195,241	$	355,437	$	332,782		$	(50,392	)	$	833,068
Cost of products sold		138,773		278,970		221,523			(50,401	)		588,865
Gross Profit		56,468		76,467		111,259			9			244,203
Selling, general and administrative expenses		67,214		53,202		85,781			0			206,197
Loss on debt extinguishment including debt finance charges and associated fees		18,434		0		0			0			18,434
Income (loss) from equity investee		42,447		8,834		(384	)		(50,897	)		0
Interest expense - net		9,779		309		1,764			0			11,852
Earnings (loss) before Income Taxes		3,488		31,790		23,330			(50,888	)		7,720
Income taxes		993		553		3,679			0			5,225
Net Earnings (loss)	$	2,495	$	31,237	$	19,651		$	(50,888	)	$	2,495

CONSOLIDATING CONDENSED BALANCE SHEETS

(in thousands) June 30, 2011	The     Company     (Parent)		Combined Guarantor     Subsidiaries		Combined  Non-Guarantor  Subsidiaries		Eliminations			Total
Assets
Current Assets
Cash and cash equivalents	$	4,706	$	1,976	$	31,480	$	0		$	38,162
Trade receivables, net		90,870		71,289		106,594		0			268,753
Installment receivables, net		0		1,252		4,725		0			5,977
Inventories, net		41,334		41,579		107,399		(1,500	)		188,812
Deferred income taxes		3,431		0		2,589		0			6,020
Other current assets		12,238		5,775		32,839		(1,318	)		49,534
Total Current Assets		152,579		121,871		285,626		(2,818	)		557,258
Investment in subsidiaries		1,605,100		568,810		0		(2,173,910	)		0
Intercompany advances, net		78,729		815,660		201,985		(1,096,374	)		0
Other Assets		42,768		1,049		1,356		0			45,173
Other Intangibles		1,036		7,956		63,279		0			72,271
Property and Equipment, net		46,530		12,565		74,942		0			134,037
Goodwill		5,023		34,386		514,095		0			553,504
Total Assets	$	1,931,765	$	1,562,297	$	1,141,283	$	(3,273,102	)	$	1,362,243
Liabilities and Shareholders' Equity
Current Liabilities
Accounts payable	$	79,159	$	17,657	$	63,806	$	0		$	160,622
Accrued expenses		31,346		22,129		82,131		(1,318	)		134,288
Accrued income taxes		928		0		477		0			1,405
Short-term debt and current maturities of long-term obligations		7,609		68		754		0			8,431
Total Current Liabilities		119,042		39,854		147,168		(1,318	)		304,746
Long-Term Debt		234,798		0		12,499		0			247,297
Other Long-Term Obligations		51,445		1,100		54,710		0			107,255
Intercompany advances, net		823,535		175,036		97,806		(1,096,377	)		0
Total Shareholders' Equity		702,945		1,346,307		829,100		(2,175,407	)		702,945
Total Liabilities and Shareholders' Equity	$	1,931,765	$	1,562,297	$	1,141,283	$	(3,273,102	)	$	1,362,243

CONSOLIDATING CONDENSED BALANCE SHEETS

(in thousands) December 31, 2010	The     Company     (Parent)		Combined Guarantor     Subsidiaries		Combined  Non-Guarantor  Subsidiaries		Eliminations			Total
Assets
Current Assets
Cash and cash equivalents	$	4,036	$	2,476	$	41,950	$	0		$	48,462
Trade receivables, net		95,673		68,504		87,827		0			252,004
Installment receivables, net		0		876		3,083		0			3,959
Inventories, net		72,499		39,299		63,873		(1,296	)		174,375
Deferred income taxes		3,289		0		2,489		0			5,778
Other current assets		12,274		6,895		27,685		(5,273	)		41,581
Total Current Assets		187,771		118,050		226,907		(6,569	)		526,159
Investment in subsidiaries		1,489,732		594,690		0		(2,084,422	)		0
Intercompany advances, net		77,990		745,991		226,421		(1,050,402	)		0
Other Assets		42,782		1,881		821		0			45,484
Other Intangibles		1,241		8,590		61,080		0			70,911
Property and Equipment, net		46,791		12,093		71,879		0			130,763
Goodwill		5,023		34,388		467,672		0			507,083
Total Assets	$	1,851,330	$	1,515,683	$	1,054,780	$	(3,141,393	)	$	1,280,400
Liabilities and Shareholders' Equity
Current Liabilities
Accounts payable	$	73,468	$	14,923	$	55,362	$	0		$	143,753
Accrued expenses		39,090		20,690		75,572		(5,273	)		130,079
Accrued income taxes		5,633		0		2,869		0			8,502
Short-term debt and current maturities of long-term obligations		7,149		83		742		0			7,974
Total Current Liabilities		125,340		35,696		134,545		(5,273	)		290,308
Long-Term Debt		217,164		0		20,926		0			238,090
Other Long-Term Obligations		48,645		1,123		49,823		0			99,591
Intercompany advances, net		807,770		180,743		61,889		(1,050,402	)		0
Total Shareholders' Equity		652,411		1,298,121		787,597		(2,085,718	)		652,411
Total Liabilities and Shareholders' Equity	$	1,851,330	$	1,515,683	$	1,054,780	$	(3,141,393	)	$	1,280,400

CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS

(in thousands) Six month period ended June 30, 2011	The     Company     (Parent)			Combined Guarantor     Subsidiaries			Combined Non-Guarantor Subsidiaries			Eliminations			Total
Net Cash Provided (Used) by Operating Activities	$	35,442		$	(1,643	)	$	27,314		$	(24,117	)	$	36,996
Investing Activities
Purchases of property and equipment		(3,818	)		(1,807	)		(4,479	)		0			(10,104	)
Proceeds from sale of property and equipment		0			15			22			0			37
(Increase) decrease in other long-term assets		(1,016	)		0			5			0			(1,011	)
Business acquisitions, net of cash acquired		0			0			0			0			(0	)
Other		5			1			(82	)		0			(76	)
Net Cash Used for Investing Activities		(4,829	)		(1,791	)		(4,534	)		0			(11,154	)
Financing Activities
Proceeds from revolving lines of credit and long-term borrowings		227,818			2,934			0			0			230,752
Payments on revolving lines of credit and long-term debt and capital lease obligations		(226,739	)		0			(11,142	)		0			(237,881	)
Proceeds from exercise of stock options		4,101			0			0			0			4,101
Payment of financing costs		(18,116	)		0			0			0			(18,116	)
Payment of dividends		(794	)		0			(24,117	)		24,117			(794	)
Purchase of treasury stock		(16,213	)		0			0			0			(16,213	)
Net Cash Provided (Used) by Financing Activities		(29,943	)		2,934			(35,259	)		24,117			(38,151	)
Effect of exchange rate changes on cash		0			0			2,009			0			2,009
Increase (decrease) in cash and cash equivalents		670			(500	)		(10,470	)		0			(10,300	)
Cash and cash equivalents at beginning of period		4,036			2,476			41,950			0			48,462
Cash and cash equivalents at end of period	$	4,706		$	1,976		$	31,480		$	0		$	38,162

CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS

(in thousands) Six month period ended June 30, 2010	The     Company     (Parent)			Combined Guarantor     Subsidiaries			Combined Non- Guarantor  Subsidiaries			Eliminations		Total
Net Cash Provided (Used) by Operating Activities	$	40,095		$	14,764		$	(779	)	$	0	$	54,080
Investing Activities
Purchases of property and equipment		(4,200	)		(246	)		(3,976	)		0		(8,422	)
Proceeds from sale of property and equipment					(2	)		315			0		313
(Increase) decrease in other long-term assets		368			(11	)		456			0		813
Business acquisitions, net of cash acquired					(13,725	)		0			0		(13,725	)
Other		301			(10	)		(514	)		0		(223	)
Net Cash Used for Investing Activities		(3,531	)		(13,994	)		(3,719	)		0		(21,244	)
Financing Activities
Proceeds from revolving lines of credit and long-term borrowings		197,209			0			4,452			0		201,661
Payments on revolving lines of credit and long-term debt and capital lease obligations		(219,847	)		0			0			0		(219,847	)
Proceeds from exercise of stock options		1,002			0			0			0		1,002
Payment of financing costs		(16,549	)		0			0			0		(16,549	)
Payment of dividends		(808	)		0			0			0		(808	)
Net Cash Provided (Used) by Financing Activities		(38,993	)		0			4,452			0		(34,541	)
Effect of exchange rate changes on cash		0			0			(4,591	)		0		(4,591	)
Increase (decrease) in cash and cash equivalents		(2,429	)		770			(4,637	)		0		(6,296	)
Cash and cash equivalents at beginning of period		6,569			2,526			28,406			0		37,501
Cash and cash equivalents at end of period	$	4,140		$	3,296		$	23,769		$	0	$	31,205

XML



Document and Entity Information	6 Months Ended
	Jun. 30, 2011	Aug. 02, 2011 Common Class A [Member]	Aug. 02, 2011 Common Class B [Member]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2011
Entity Registrant Name	INVACARE CORP
Entity Central Index Key	0000742112
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2011
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		30,872,004	1,084,747

XML



Long-Term Debt

6 Months Ended

Jun. 30, 2011

Long-Term Debt

Long-Term Debt

Long-Term Debt - On May 9, 2008, Staff Position APB 14-1, Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement) (FSP APB 14-1) as codified in Debt with Conversion and Other Options, ASC 470-20, was issued to provide clarification of the accounting for convertible debt that can be settled in cash upon conversion. The FASB believed this clarification was needed because the accounting that was being applied for convertible debt prior to FSP APB 14-1 did not fully reflect the true economic impact on the issuer since the conversion option was not captured as a borrowing cost and its full dilutive effect was not included in earnings per share. ASC 470-20 required separate accounting for the liability and equity components of the convertible debt in a manner that would reflect Invacare's nonconvertible debt borrowing rate. Accordingly, the Company initially split the total debt amount of $135,000,000 attributable to its 4.125% Convertible Senior Subordinated Debentures due 2027 into a convertible debt amount of $75,988,000 and a stockholders' equity (debt discount) amount of $59,012,000 as of the retrospective adoption date of February 12, 2007 and is accreting the resulting debt discount as interest expense over a ten year life. The Consolidated Balance Sheet as of June 30, 2011 reflects a decrease in long-term debt of $9,708,000 and a deferred tax liability of $3,398,000 compared to comparable amounts of $25,137,000 and $8,798,000, respectively, as of December 31, 2010.

During the six months ended June 30, 2011, the Company repurchased $45,814,000 ($30,385,000 reduction of debt and $15,429,000 reduction of equity) principal amount of its 4.125% Convertible Senior Subordinated Debentures due 2027. The Company retired the debt at a premium above par. In accordance with Convertible Debt, ASC 470-20, the Company utilized the inducement method of accounting to calculate the loss associated with the early retirement of the convertible debt. For the three and six months ended June 30, 2011, the Company recorded pre-tax expense of $11,855,000 and $16,736,000, respectively, related to the loss on the debt extinguishment including the write-off of $792,000 and $1,128,000 of pre-tax of deferred financing fees, which were previously capitalized, for the three and six months ended June 30, 2011.

The Company utilized primarily its cash and cash flows from operations as well as its revolving line of credit to pay down the debt noted above. At June 30, 2011, the Company had outstanding $224,458,000 on its revolving line of credit compared to $184,932,000 as of December 31, 2010.

During the first six months of 2011, the Company entered into interest rate swap agreements to effectively convert a portion of floating rate revolving credit facility debt to fixed rate debt to avoid the risk of changes in market interest rates. Specifically, interest rate swap agreements for notional amounts of $18,000,000 through June 2013, $20,000,000 and $25,000,000 through May 2013 and $15,000,000 through February 2013 were entered into that fix the LIBOR component of the interest rate on that portion of the revolving credit facility debt at rates of 0.625%, 1.08%, 0.73% and 1.05%, respectively, for effective aggregate rates of 2.375%, 2.83%, 2.48% and 2.80%, respectively.

XML



Concentration of Credit Risk

6 Months Ended

Jun. 30, 2011

Concentration of Credit Risk

Concentration of Credit Risk

Concentration of Credit Risk - The Company manufactures and distributes durable medical equipment and supplies to the home health care, retail and extended care markets. The Company performs credit evaluations of its customers' financial condition. In December 2000, Invacare entered into an agreement with DLL, a third party financing company, to provide the majority of future lease financing to Invacare's North America customers. The DLL agreement provides for direct leasing between DLL and the Invacare customer. The Company retains a recourse obligation to DLL, which was $25,028,000 at June 30, 2011, for events of default under the contracts, which total $68,630,000 at June 30, 2011. Guarantees, ASC 460, requires the Company to record a guarantee liability as it relates to the limited recourse obligation. As such, the Company has recorded a liability of $598,000 for this guarantee obligation within accrued expenses. The Company monitors the collections status of these contracts and has provided amounts for estimated losses in its allowances for doubtful accounts in accordance with Receivables, ASC 310-10-05-4. Credit losses are provided for in the financial statements.

Substantially all of the Company's receivables are due from health care, medical equipment providers and long term care facilities located throughout the United States, Australia, Canada, New Zealand and Europe. A significant portion of products sold to dealers, both foreign and domestic, is ultimately funded through government reimbursement programs such as Medicare and Medicaid. In addition, the Company has also seen a significant shift in reimbursement to customers from managed care entities. As a consequence, changes in these programs can have an adverse impact on dealer liquidity and profitability. In addition, reimbursement guidelines in the home health care industry have a substantial impact on the nature and type of equipment an end user can obtain as well as the timing of reimbursement and, thus, affect the product mix, pricing and payment patterns of the Company's customers.

XML



Inventories

6 Months Ended

Jun. 30, 2011

Inventories

Inventories

Inventories - Inventories determined under the first in, first out method consist of the following components (in thousands):

	June 30, 2011		December 31, 2010
Finished goods	$	114,857	$	101,243
Raw Materials		63,423		59,921
Work in Process		10,532		13,211
	$	188,812	$	174,375

XML



Comprehensive Earnings (loss)

6 Months Ended

Jun. 30, 2011

Comprehensive Earnings (loss)

Comprehensive Earnings (loss)

Comprehensive Earnings (loss) - Total comprehensive earnings (loss) were as follows (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2011			2010			2011			2010
Net earnings (loss)	$	10,661		$	(611	)	$	18,115		$	2,495
Foreign currency translation gain (loss)		25,560			(60,747	)		60,993			(110,887	)
SERP/DBO amortization of prior service costs and unrecognized losses		(209	)		151			(420	)		308
Current period unrealized gain (loss) on cash flow hedges, net of tax		(15	)		(146	)		(1,299	)		2,367
Total comprehensive earnings (loss)	$	35,997		$	(61,353	)	$	77,389		$	(105,717	)

XML



Fair Value Measurements

6 Months Ended

Jun. 30, 2011

Fair Value Measurements

Fair Value Measurements

Fair Value Measurements - Pursuant to ASC 820, the inputs used to derive the fair value of assets and liabilities are analyzed and assigned a level of I, II or III, with level I being the highest and level III being the lowest in the hierarchy. Level I inputs are quoted prices in active markets for identical assets or liabilities. Level II inputs are quoted prices for similar assets or liabilities in active markets: quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. Level III inputs are based on valuations derived from valuation techniques in which one or more significant inputs are unobservable.

The following table provides a summary of the Company's assets and liabilities that are measured on a recurring basis (in thousands):

				Basis for Fair Value Measurements at Reporting  Date
				Quoted Prices in  Active Markets for Identical Assets / (Liabilities)		Significant Other   Observable  Inputs			Significant Other        Unobservable Inputs
	Total			Level I		Level II			Level III
June 30, 2011
Forward Exchange Contracts-net	$	395		$	0	$	395		$	0
Swaps		(416	)		0		(416	)		0
December 31, 2010
Forward Exchange Contracts-net	$	955		$	0	$	955		$	0

Forward Contracts: The Company operates internationally and as a result is exposed to foreign currency fluctuations. Specifically, the exposure includes intercompany trade receivables/payables and loans as well as third party sales or purchases. In an attempt to reduce this exposure, foreign currency forward contracts are utilized and accounted for as hedging instruments. The forward contracts are used to hedge various currencies. The Company does not use derivative financial instruments for speculative purposes. Fair values for the Company's foreign exchange forward contracts are based on quoted market prices for contracts with similar maturities.

The carrying amounts and fair values of the Company's financial instruments at June 30, 2011 and December 31, 2010 are as follows (in thousands):

	June 30, 2011						December 31, 2010
	Carrying     Value			Fair Value			Carrying     Value			Fair Value
Cash and cash equivalents	$	38,162		$	38,162		$	48,462		$	48,462
Other investments		1,590			1,590			1,588			1,588
Installment receivables, net		7,281			7,281			5,672			5,672
Long-term debt (including current maturities of long-term debt) *		(255,728	)		(264,489	)		(246,064	)		(264,382	)
Forward contracts in other current assets		3,580			3,580			2,884			2,884
Interest rate swap agreements in accrued expenses		(416	)		(416	)		0			0
Forward contracts in accrued expenses		(3,185	)		(3,185	)		(1,929	)		(1,929	)

* The carrying amounts and fair values exclude convertible debt classified as equity in accordance with FSP APB 14-1 ($9,708,000 and $25,137,000 as of June 30, 2011 and December 31, 2010, respectively).

XML



Income Taxes

6 Months Ended

Jun. 30, 2011

Income Taxes

Income Taxes

Income Taxes - The Company had an effective tax rate of (29.1)% and 0.8% on earnings before tax for the three and six month periods ended June 30, 2011 compared to an expected rate at the US statutory rate of 35%. The Company's effective tax rate for the three and six months ended June 30, 2011 was lower than the U.S. federal statutory rate, principally due to foreign taxes recognized at rates below the U.S. statutory rate including a second quarter $5,100,000 ($0.16 per share) tax benefit as a result of a tax settlement in Germany as the German government agreed to follow a European Court of Justice case and a German Tax Court case that impacted an open tax return year. The net impact of tax benefit from countries with valuation allowances on the Company's effective tax rate was minimal for the first half of 2011. The Company had an effective tax rate of 125.3% and 67.7% on earnings before tax for the three and six month periods ended June 30, 2010, respectively, compared to an expected rate at the U.S. statutory rate of 35%. The Company's effective tax rate for the three and six month periods ended June 30, 2010 was higher than the U.S. federal statutory rate as a result of the significant negative impact of the Company not being able to record tax benefits related to losses in countries which had tax valuation allowances. The Company continued to be in a loss position in the U.S. principally as a result of recording pre-tax expenses of $11,855,000 and $16,736,000 for the three and six months ended June 30, 2011, respectively, related to the extinguishment of convertible debt at a premium.

XML



Shareholders' Equity Transactions

6 Months Ended

Jun. 30, 2011

Shareholders' Equity Transactions

Shareholders' Equity Transactions

Shareholders' Equity Transactions - The 2003 Plan allows the Compensation and Management Development Committee of the Board of Directors (the "Committee") to grant up to 6,800,000 Common Shares in connection with incentive stock options, non-qualified stock options, stock appreciation rights and stock awards (including the use of restricted stock). The maximum aggregate number of Common Shares that may be granted during the term of the 2003 Plan pursuant to all awards, other than stock options, is 1,300,000 Common Shares. The Committee has the authority to determine which employees and directors will receive awards, the amount of the awards and the other terms and conditions of the awards. During the first six months of 2011, the Committee granted non-qualified stock options to purchase 9,496 Common Shares with a term of ten years at the fair market value of the Company's Common Shares on the date of grant under the 2003 Plan, which vest ratably in annual installments over the four years following the grant date.

Under the terms of the Company's outstanding restricted stock awards, all of the shares granted vest ratably over the four years after the grant date. Compensation expense of $1,028,000 was recognized related to restricted stock awards in the first six months of 2011 and, as of June 30, 2011, outstanding restricted stock awards totaling 236,870 shares were not yet vested.

As of June 30, 2011, there was $12,380,000 of total unrecognized compensation cost from stock-based compensation arrangements granted under the 2003 Plan, which is related to non-vested options and shares, and includes $3,920,000 related to restricted stock awards. The Company expects the compensation expense to be recognized over a four-year period for a weighted-average period of approximately two years.

Stock option activity during the six months ended June 30, 2011 was as follows:

	2011			Weighted Average            Exercise Price
Options outstanding at January 1		4,484,195		$	29.60
Granted		9,496			31.94
Exercised		(176,649	)		23.22
Canceled		(75,872	)		30.79
Options outstanding at June 30		4,241,170		$	29.86
Options price range at June 30	$	10.70 to
	$	47.80
Options exercisable at June 30		2,740,773
Options available for grant at June 30*		2,520,386

* Options available for grant as of June 30, 2011 reduced by net restricted stock award activity of 482,678.

The following table summarizes information about stock options outstanding at June 30, 2011:

	Options Outstanding						Options Exercisable
Exercise Prices	Number Outstanding At  6/30/11		Weighted Average  Remaining Contractual Life		Weighted Average Exercise  Price		Number Exercisable At 6/30/11		Weighted Average Exercise Price
$ 10.70 - $15.00		19,925		1.2 years	$	10.80		19,425	$	10.70
$ 15.00 - $25.00		1,303,926		6.9	$	21.66		670,699	$	22.36
$ 25.01 - $35.00		1,553,228		6.1	$	27.50		686,558	$	30.03
$ 35.01 - $47.80		1,364,091		2.9	$	40.67		1,364,091	$	40.67
Total		4,241,170		5.3	$	29.86		2,740,773	$	33.31

When stock options are awarded, they generally become exercisable over a four-year vesting period whereby options vest in equal installments each year. Options granted with graded vesting are accounted for as single options. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model with assumptions for expected dividend yield, expected stock price volatility, risk-free interest rate and expected life. The assumed expected life is based on the Company's historical analysis of option history. The expected stock price volatility is also based on actual historical volatility, and expected dividend yield is based on historical dividends as the Company has no current intention of changing its dividend policy.

The 2003 Plan provides that shares granted come from the Company's authorized but unissued Common Shares or treasury shares. In addition, the Company's stock-based compensation plans allow employee participants to exchange shares for minimum withholding taxes, which results in the Company acquiring treasury shares.

Pursuant to the Company's Board of Directors authorized plan to purchase up to 2,000,000 Common Shares, excluding any shares acquired from employees or directors as a result of the exercise of options or vesting of restricted shares pursuant to the Company's performance plans, the Company purchased a total of 540,900 shares for an aggregate purchase price of $16,213,000 during the first six months of 2011.

XML



Accounting for Stock-Based Compensation

6 Months Ended

Jun. 30, 2011

Accounting for Stock-Based Compensation

Accounting for Stock-Based Compensation

Accounting for Stock-Based Compensation - The Company accounts for share based compensation under the provisions of Compensation—Stock Compensation, ASC 718. The Company has not made any modifications to the terms of any previously granted options and no significant changes have been made regarding the valuation methodologies used to determine the fair value of options granted and the Company continues to use a Black-Scholes valuation model.

The substantial majority of the options awarded have been granted at exercise prices equal to the market value of the underlying stock on the date of grant. Restricted stock awards granted without cost to the recipients are expensed on a straight-line basis over the vesting periods.

The amounts of stock-based compensation expense recognized were as follows (in thousands):

	Three Months Ended June  30,				Six Months Ended June 30,
	2011		2010		2011		2010
Stock-based compensation expense recognized as part of selling, general and administrative expense	$	1,467	$	1,283	$	2,878	$	2,840

The amounts above reflect compensation expense related to restricted stock awards and nonqualified stock options awarded under the 2003 Performance Plan (the "2003 Plan"). Stock-based compensation is not allocated to the business segments, but is reported as part of All Other as shown in the Company's Business Segment Note to the Consolidated Financial Statements.

XML



Property and Equipment

6 Months Ended

Jun. 30, 2011

Property and Equipment

Property and Equipment

Property and Equipment - Property and equipment consist of the following (in thousands):

	June 30, 2011			December 31, 2010
Machinery and equipment	$	351,415		$	332,687
Land, buildings and improvements		98,550			91,956
Furniture and fixtures		28,844			27,775
Leasehold improvements		16,462			15,705
		495,271			468,123
Less allowance for depreciation		(361,234	)		(337,360	)
	$	134,037		$	130,763

XML



Goodwill and Other Intangibles

6 Months Ended

Jun. 30, 2011

Goodwill and Other Intangibles

Goodwill and Other Intangibles

Goodwill and Other Intangibles - The change in goodwill reflected on the balance sheet from December 31, 2010 to June 30, 2011 was entirely the result of foreign currency translation.

All of the Company's other intangible assets have been assigned definite lives and continue to be amortized over their useful lives, except for $33,963,000 related to trademarks, which have indefinite lives. The changes in intangible balances reflected on the balance sheet from December 31, 2010 to June 30, 2011 were the result of foreign currency translation and amortization.

As of June 30, 2011 and December 31, 2010, other intangibles consisted of the following (in thousands):

	June 30, 2011				December 31, 2010
	Historical       Cost		Accumulated       Amortization		Historical       Cost		Accumulated       Amortization
Customer lists	$	79,948	$	47,729	$	72,998	$	40,071
Trademarks		33,963		0		31,246		0
License agreements		3,243		3,015		3,183		2,958
Developed technology		9,496		4,745		8,521		3,988
Patents		6,028		5,162		7,518		5,863
Other		6,205		5,961		6,092		5,767
	$	138,883	$	66,612	$	129,558	$	58,647

Amortization expense related to other intangibles was $4,338,000 in the first six months of 2011 and is estimated to be $8,124,000 in 2012, $7,321,000 in 2013, $6,926,000 in 2014, $5,614,000 in 2015 and $4,150,000 in 2016. Definite lived intangibles are being amortized on a straight-line basis for periods from 3 to 20 years with the majority of the intangibles being amortized over a life of between 10 and 13 years.

XML



Derivatives

6 Months Ended

Jun. 30, 2011

Derivatives

Derivatives

Derivatives -Derivatives and Hedging, ASC 815, requires companies to recognize all derivative instruments in the consolidated balance sheet as either assets or liabilities at fair value. The accounting for changes in fair value of a derivative is dependent upon whether or not the derivative has been designated and qualifies for hedge accounting treatment and the type of hedging relationship. For derivatives designated and qualifying as hedging instruments, the Company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation.

Cash Flow Hedging Strategy

The Company uses derivative instruments in an attempt to manage its exposure to commodity price risk, foreign currency exchange risk and interest rate risk. Foreign exchange contracts are used to manage the price risk associated with forecasted sales denominated in foreign currencies and the price risk associated with forecasted purchases of inventory over the next twelve months. Interest rate swaps are, at times, utilized to manage interest rate risk associated with the Company's fixed and floating-rate borrowings.

The Company recognizes its derivative instruments as assets or liabilities in the consolidated balance sheet measured at fair value. A majority of the Company's derivative instruments are designated and qualify as cash flow hedges. Accordingly, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. The remaining gain or loss on the derivative instrument in excess of the cumulative change in the fair value of the hedged item, if any, is recognized in current earnings during the period of change.

Effective April 5, 2011, the Company entered into an amendment to its credit agreement that, among other things, reduced the applicable interest rate related to both LIBOR and Base Rate option borrowings by 75 basis points. During the first six months of 2011, the Company entered into interest rate swap agreements to effectively convert a portion of floating rate revolving credit facility debt to fixed rate debt to avoid the risk of changes in market interest rates. Specifically, interest rate swap agreements for notional amounts of $18,000,000 through June 2013, $20,000,000 and $25,000,000 through May 2013 and $15,000,000 through February 2013 were entered into that fix the LIBOR component of the interest rate on that portion of the revolving credit facility debt at rates of 0.625%, 1.08%, 0.73% and 1.05%, respectively, for effective aggregate rates of 2.375%, 2.83%, 2.48% and 2.80%, respectively. The gains and or losses on interest rate swaps are reflected in interest expense on the consolidated statement of earnings. The Company was not a party to any interest rate swap agreements during 2010.

To protect against increases/decreases in forecasted foreign currency cash flows resulting from inventory purchases/sales over the next year, the Company utilizes foreign currency forward contracts to hedge portions of its forecasted purchases/sales denominated in foreign currencies. The gains and losses are included in cost of products sold and selling, general and administrative expenses on the consolidated statement of earnings. If it is later determined that a hedged forecasted transaction is unlikely to occur, any gains or losses on the forward contracts associated with the forecasted transactions that are no longer probable of occurring would be reclassified from other comprehensive income into earnings. The Company does not expect any material amount of hedge ineffectiveness related to forward contract cash flow hedges during the next twelve months.

The Company has historically not recognized any material amount of ineffectiveness related to forward contract cash flow hedges because the Company generally limits it hedges to between 60% and 90% of total forecasted transactions for a given entity's exposure to currency rate changes and the transactions hedged are recurring in nature. Furthermore, the majority of the hedged transactions are related to intercompany sales and purchases for which settlement occurs on a specific day each month. Forward contracts with a total notional amount in USD of $49,223,000 and $88,605,000 matured during the three and six months ended June 30, 2011, respectively, compared to forward contracts with a total notional amount in USD of $41,683,000 and $82,081,000 which matured during the three and six months ended June 30, 2010, respectively.

Foreign exchange forward contracts qualifying and designated for hedge accounting treatment were as follows (in thousands USD):

	June 30, 2011					December 31, 2010
	Notional Amount		Unrealized Gain (Loss)			Notional Amount		Unrealized Gain (Loss)
USD / AUD	$	1,536	$	(231	)	$	3,072	$	(223	)
USD / CAD		16,839		(30	)		32,974		(14	)
USD / CNY		6,444		33			0		0
USD / EUR		17,084		(1,078	)		32,419		927
USD / GBP		2,006		(84	)		4,212		86
USD / NZD		7,160		578			9,577		202
USD / SEK		5,376		30			10,395		95
USD / MXP		3,486		149			0		0
EUR / AUD		679		(27	)		0		0
EUR / CHF		2,677		(150	)		8,768		54
EUR / GBP		13,367		193			18,068		(577	)
EUR / SEK		6,131		194			8,045		92
EUR / NOK		2,287		(24	)		0		0
EUR / NZD		4,384		171			2,630		5
GBP / CHF		957		36			770		(3	)
GBP / SEK		1,326		65			2,014		(43	)
GBP / DKK		704		12			1,016		(27	)
CHF / SEK		239		(7	)		6,937		(3	)
DKK / CHF		316		(17	)		514		1
DKK / NOK		894		(10	)		0		0
DKK / SEK		3,952		9			1,465		18
NOK / SEK		413		(3	)		0		0
	$	98,257	$	(191	)	$	142,876	$	590

Fair Value Hedging Strategy

In 2011 and 2010, the Company did not utilize any derivatives designated as fair value hedges. However, the Company has in the past utilized fair value hedges in the form of forward contracts to manage the foreign exchange risk associated with certain firm commitments and has entered into interest rate swaps to effectively convert fixed-rate debt to floating-rate debt in an attempt to avoid paying higher than market interest rates. For derivative instruments designated and qualifying as fair value hedges, the gain or loss on the derivative instrument as well as the offsetting gain or loss on the hedged item associated with the hedged risk are recognized in the same line item associated with the hedged item in earnings.

Derivatives Not Qualifying or Designated for Hedge Accounting Treatment

The Company utilizes foreign currency forward or option contracts that do not qualify for hedge accounting treatment in an attempt to manage the risk associated with the conversion of earnings in foreign currencies into U.S. Dollars. While these derivative instruments do not qualify for hedge accounting treatment in accordance with ASC 815, these derivatives do provide the Company with a means to manage the risk associated with currency translation. These instruments are recorded at fair value in the consolidated balance sheet and any gains or losses are recorded as part of earnings in the current period. An immaterial gain was recorded by the Company for the three and six months ended June 30, 2011, respectively, related to these derivatives not qualifying for hedge accounting treatment, while no such derivatives existed for the three and six months ended June 30, 2010.

The Company also utilizes foreign currency forward contracts that are not designated as hedges in accordance with ASC 815 although they could qualify for hedge accounting treatment. These contracts are entered into to eliminate the risk associated with the settlement of short-term intercompany trading receivables and payables between Invacare Corporation and its foreign subsidiaries. The currency forward contracts are entered into at the same time as the intercompany receivables or payables are created so that upon settlement, the gain/loss on the settlement is offset by the gain/loss on the foreign currency forward contract. No material net gain or loss was realized by the Company for the three or six month periods ended June 30, 2011 and 2010, respectively, related to these forward contracts and the associated short-term intercompany trading receivables and payables.

Foreign exchange forward contracts not qualifying or designated for hedge accounting treatment entered into in and outstanding as of June 30, 2011 and 2010 were as follows (in thousands USD):

	June 30, 2011					June 30, 2010
	Notional Amount		Gain  (Loss)			Notional Amount		Gain  (Loss)
CAD / USD	$	0	$	0		$	9,350	$	(231	)
CHF / USD		909		43			0		0
CHF / GBP		0		0			0		0
NZD / USD		0		0			13,396		(174	)
NOK / USD		6,252		212			0		0
SEK / USD		0		0			3,187		22
DKK / USD		0		0			2,539		(76	)
DKK / NOK		149		(2	)		0		0
EUR / GBP		0		0			1,544		(68	)
EUR / SEK		19		0			118		(6	)
EUR / CAD		20,000		327			0		0
EUR / USD		0		8			11,912		(290	)
EUR / NZD		159		(2	)		0		0
	$	27,488	$	586		$	42,046	$	(823	)

The fair values of the Company's derivative instruments were as follows (in thousands):

	June 30, 2011					December 31, 2010
	Assets		Liabilities			Assets		Liabilities
Derivatives designated as hedging instruments under ASC 815
Foreign currency forward contracts	$	2,990	$	(3,181	)	$	2,518	$	1,928
Interest rate swap contracts		0		(416	)		0		0
Derivatives not designated as hedging instruments under ASC 815
Foreign currency forward contracts		590		(4	)		366		1
Total derivatives	$	3,580	$	(3,601	)	$	2,884	$	1,929

The fair values of the Company's foreign currency forward assets and liabilities are included in Other Current Assets and Accrued Expenses, respectively in the Consolidated Balance Sheets.

The effect of derivative instruments on the Statement of Earnings and Other Comprehensive Income (OCI) was as follows (in thousands):

Derivatives in ASC 815 cash flow hedge relationships	Amount of Gain   (Loss) Recognized in   OCI on Derivatives (Effective Portion)			Amount of Gain (Loss)   Reclassified from Accumulated OCI into Income (Effective Portion)			Amount of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion and Amount Excluded from Effectiveness Testing)
Quarter ended June 30, 2011:
Foreign currency forward contracts	$	410		$	(5	)	$	(10	)
Interest rate swap contracts		(287	)		0			0
	$	123		$	(5	)	$	(10	)
Six months ended June 30, 2011:
Foreign currency forward contracts	$	(838	)	$	57		$	(4	)
Interest rate swap contracts		(416	)		0			0
	$	(1,254	)	$	57		$	(4	)
Quarter ended June 30, 2010:
Foreign currency forward contracts	$	(918	)	$	840		$	(65	)
Six months ended June 30, 2010:
Foreign currency forward contracts	$	1,338		$	779		$	(39	)

Derivatives not designated as hedging instruments under ASC 815	Amount of Gain (Loss) Recognized in Income on Derivatives
Quarter ended June 30, 2011:
Foreign currency forward contracts	$	(237	)
Six months ended June 30, 2011:
Foreign currency forward contracts	$	586
Quarter ended June 30, 2010:
Foreign currency forward contracts	$	(1,144	)
Six months ended June 30, 2010:
Foreign currency forward contracts	$	(823	)

The gains or losses recognized as the result of the settlement of cash flow hedge foreign currency forward contracts are recognized in net sales for hedges of inventory sales or cost of product sold for hedges of inventory purchases. For the three and six months ended June 30, 2011, net sales were increased by $1,041,000 and $1,254,000 and cost of product sold was increased by $1,046,000 and $1,197,000 for a net realized loss of $5,000 and gain of $57,000, respectively. For the quarter and six months ended June 30 2010, net sales were increased by $426,000 and $540,000, respectively, and cost of product sold was decreased by $414,000 and $239,000 for net realized gains of $840,000 and $779,000, respectively. As the result of swap agreements outstanding in 2011, losses of $77,000 and $118,000 were recorded for the three and six months ended June 30, 2011 which were recorded in interest expense. No swap agreements were outstanding in 2010.

A loss of $227,000 and a gain of $590,000 was recognized in selling, general and administrative (SG&A) expenses for the three and six months ended June 30, 2011, respectively, compared to losses of $1,144,000 and $823,000 for the three and six months ended June 30, 2010 on foreign currency forward contracts not designated as hedging instruments, which were substantially offset by foreign currency gains/losses also recorded in SG&A expenses on the intercompany trade payables for which the derivatives were entered into to offset. In addition, losses of $10,000 and $4,000 were recognized for the three and six months ended June 30, 2011, respectively, compared to losses of $65,000 and $39,000 for the three and six months ended June 30, 2010, respectively, related to derivatives no longer qualifying for hedge accounting treatment as the forecasted transactions hedged by those derivatives were no longer probable of occurring and as a result, the hedging relationship was ineffective.

XML



Warranty Costs

6 Months Ended

Jun. 30, 2011

Warranty Costs

Warranty Costs

Warranty Costs - Generally, the Company's products are covered from the date of sale to the customer by warranties against defects in material and workmanship for various periods depending on the product. Certain components carry a lifetime warranty. A provision for estimated warranty cost is recorded at the time of sale based upon actual experience. The Company continuously assesses the adequacy of its product warranty accrual and makes adjustments as needed. Historical analysis is primarily used to determine the Company's warranty reserves. Claims history is reviewed and provisions are adjusted as needed. However, the Company does consider other events, such as a product recall, which could warrant additional warranty reserve provision. No material adjustments to warranty reserves were necessary in the first six months of 2011.

The following is a reconciliation of the changes in accrued warranty costs for the reporting period (in thousands):

Balance as of January 1, 2011	$	18,252
Warranties provided during the period		4,617
Settlements made during the period		(5,107	)
Changes in liability for pre-existing warranties during the period, including expirations		1,895
Balance as of June 30, 2011	$	19,657

XML



Charges Related to Restructuring Activities

6 Months Ended

Jun. 30, 2011

Charges Related to Restructuring Activities

Charges Related to Restructuring Activities

Charges Related to Restructuring Activities – During the quarter ended June 30, 2011, the Company announced that it intends to close a European assembly facility as part of the Company's ongoing globalization initiative to reduce complexity within the Company's global supply chain footprint. The Company intends to transfer assembly activities to other Company facilities or outsource them to third parties. To date, the Company has recorded restructuring charges of $431,000 for severance related to the European segment, which are expected to be utilized during the next twelve months. The Company will have additional charges related to the closing of the facility, as it is not expected to be complete until the first quarter of 2012.

XML



Nature of Operations

6 Months Ended

Jun. 30, 2011

Nature of Operations

Nature of Operations, Consolidation and Presentation of Financial Statements and Significant Accounting Policies

Nature of Operations - Invacare Corporation is the world's leading manufacturer and distributor in the estimated $11.0 billion worldwide market for medical equipment and supplies used in the home based upon the Company's distribution channels, breadth of product line and net sales. The Company designs, manufactures and distributes an extensive line of health care products for the non-acute care environment, including the home health care, retail and extended care markets.

Principles of Consolidation - The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and include all adjustments, which were of a normal recurring nature, necessary to present fairly the financial position of the Company as of June 30, 2011, the results of its operations for the three and six months ended June 30, 2011 and changes in its cash flow for the six months ended June 30, 2011 and 2010, respectively. Certain foreign subsidiaries, represented by the European segment, are consolidated using a May 31 quarter end in order to meet filing deadlines. No material subsequent events have occurred related to the European segment, which would require disclosure or adjustment to the Company's financial statements. All significant intercompany transactions are eliminated. The results of operations for the three and six months ended June 30, 2011 are not necessarily indicative of the results to be expected for the full year.

Use of Estimates - The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States, which require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates.

XML



Contingencies

6 Months Ended

Jun. 30, 2011

Contingencies

Contingencies

Contingencies – In the ordinary course of its business, the Company is a defendant in a number of lawsuits, primarily product liability actions in which various plaintiffs seek damages for injuries allegedly caused by defective products. All of the product liability lawsuits have been referred to the company's captive insurance company and/or excess insurance carriers and generally are contested vigorously. The coverage territory of the Company's insurance is worldwide with the exception of those countries with respect to which, at the time the product is sold for use or at the time a claim is made, the U.S. government has suspended or prohibited diplomatic or trade relations. The amount recorded for identified contingent liabilities is based on estimates. Amounts recorded are reviewed periodically and adjusted to reflect additional technical and legal information that becomes available. Actual costs to be incurred in future periods may vary from the estimates, given the inherent uncertainties in evaluating certain exposures. Subject to the imprecision in estimating future contingent liability costs, the company does not expect that any sum it may have to pay in connection with these matters in excess of the amounts recorded will have a materially adverse effect on its financial position, results of operations or liquidity.

As a medical device manufacturer, the company is subject to extensive government regulation, including numerous laws directed at preventing fraud and abuse and laws regulating reimbursement under various government programs. The marketing, invoicing, documentation and other practices of health care suppliers and manufacturers are all subject to government scrutiny. Violations of law, regulations, licensing or registration requirements can result in administrative, civil and criminal penalties and sanctions, including disqualification from the licensing or certification required for the sale of products or for the reimbursement therefore, in the U.S., Canada, Australia, New Zealand, relevant European countries and China, which could have a material adverse effect on the Company's business. By way of further example, the Food & Drug Administration (FDA) regulates virtually all aspects of a medical device's development, testing, manufacturing, labeling, promotion, distribution and marketing in the U.S. Any failure by the Company to comply with the regulatory requirements of the FDA or other applicable regulatory requirements may subject the Company to administrative or judicially imposed sanctions. These sanctions include warning letters, civil penalties, criminal penalties, injunctions, consent decrees, product seizures or detention, product recalls and total or partial suspensions of production.

The Company continues to work on the improvements and corrective actions that it is making in response to regulatory compliance concerns raised by the FDA, including as a result of the FDA warning letter that was previously disclosed by the Company.

Any of the above contingencies could have an adverse impact on the company's financial condition or results of operations.

XML



Receivables

6 Months Ended

Jun. 30, 2011

Receivables

Receivables

Receivables - Accounts receivable and installment receivables are reduced by an allowance for amounts that may become uncollectible in the future. Substantially all of the Company's receivables are due from health care, medical equipment providers and long term care facilities located throughout the United States, Australia, Canada, New Zealand and Europe. A significant portion of products sold to providers, both foreign and domestic, is ultimately funded through government reimbursement programs such as Medicare and Medicaid in the U.S. As a consequence, changes in these programs can have an adverse impact on dealer liquidity and profitability. The estimated allowance for uncollectible amounts for both trade accounts receivable and installment receivables ($30,612,000 and $30,168,000 at June 30, 2011 and December 31, 2010, respectively) is based primarily on management's evaluation of the financial condition of specific customers. In addition, as a result of the third party financing arrangement with De Lage Landen, Inc. (DLL), a third party financing company which the Company has worked with since 2000, management monitors the collection status of these contracts in accordance with the Company's limited recourse obligations and provides amounts necessary for estimated losses in the allowance for doubtful accounts and establishing reserves for specific customers as needed. The Company charges off uncollectible trade accounts receivable after such receivables are moved to collection status and legal remedies are exhausted. See Concentration of Credit Risk in the Notes to the Consolidated Financial Statements for a description of the financing arrangement. Long-term installment receivables are included in "Other Assets" on the consolidated balance sheet.

The Company's U.S. customers electing to finance their purchases can do so using DLL. In addition, Invacare often provides financing directly for its Canadian customers for which DLL is not an option, as DLL typically provides financing to Canadian customers only on a limited basis. The installment receivables recorded on the books of the Company represent a single portfolio segment of finance receivables to the independent provider channel. The portfolio segment is comprised of two classes of receivables distinguished by geography and credit quality. The U.S. installment receivables are the first class and represent installment receivables re-purchased from DLL because the customers were in default. Default with DLL is defined as a customer being delinquent by three payments. The Canadian installment receivables represent the second class of installment receivables which were originally financed by Invacare because third party financing was not available to the HME providers. The Canadian installment receivables are typically financed for twelve months and historically have had a very low risk of default.

The estimated allowance for uncollectible amounts and evaluation for impairment for both classes of installment receivables is based on the Company's quarterly review of the financial condition of each individual customer with the allowance for doubtful accounts adjusted accordingly. Installments are individually and not collectively reviewed for impairment. The Company assesses the bad debt reserve levels based upon the status of the customer's adherence to a legally negotiated payment schedule and the Company's ability to enforce judgments, liens, etc.

For purposes of granting or extending credit, the Company utilizes a scoring model to generate a composite score that considers each customer's consumer credit score and or D&B credit rating, payment history, security collateral and time in business. Additional analysis is performed for customers desiring credit greater than $250,000 which includes a detailed review of the customer's financials as well as consideration of other factors such as exposure to changing reimbursement laws.

Interest income is recognized on installment receivables based on the terms of the installment agreements. Installment accounts are monitored and if a customer defaults on payments and is moved to collection, interest income is no longer recognized. Subsequent payments received once an account is put on non-accrual status are generally first applied to the principal balance and then to the interest. Accruing of interest on collection accounts does not occur and accruing of interest would only be restarted if the account became current again. All installment accounts are accounted for using the same methodology regardless of the duration of the installment agreements. When an account is placed in collection status, the Company initiates a legal process of adjudication of the delinquency, the duration of which is typically approximately 18 months. Any write-offs of uncollectible amounts are made after the legal process has been completed. The Company has not made any changes to either its accounting policies or methodology to estimation allowances for doubtful accounts in the last twelve months.

Installment receivables consist of the following (in thousands):

	June 30, 2011									December 31, 2010
	Current			Long-     Term			Total			Current			Long-     Term			Total
Installment receivables	$	7,938		$	4,057		$	11,995		$	5,777		$	4,854		$	10,631
Less: Unearned interest		(192	)		0			(192	)		(118	)		0			(118	)
		7,746			4,057			11,803			5,659			4,854			10,513
Allowance for doubtful accounts		(1,769	)		(2,753	)		(4,522	)		(1,700	)		(3,141	)		(4,841	)
	$	5,977		$	1,304		$	7,281		$	3,959		$	1,713		$	5,672

Installment receivable purchased from DLL during the six months ended June 30, 2011 increased the gross installment receivables balance by $2,116,000. No sales of installment receivables were made by the Company during the year.

The movement in the installment receivables allowance for doubtful accounts was as follows (in thousands):

	Six Months Ended          June 30, 2011			Year Ended   December 31,  2010
Beginning Balance	$	4,841		$	6,080
Current period provision		857			4,022
Direct write-offs charged against the allowance		(1,176	)		(5,261	)
Ending Balance	$	4,522		$	4,841

Installment receivables by class as of June 30, 2011 consist of the following (in thousands):

U.S.	Total Installment Receivables		Unpaid Principal   Balance		Related Allowance for Doubtful   Accounts		Interest Income  Recognized
Impaired Installment receivables with a related allowance recorded	$	6,784	$	6,784	$	4,482	$	0
Canada
Non-Impaired Installment receivables with no related allowance recorded		5,171		4,979		0		117
Impaired Installment receivables with a related allowance recorded		40		40		40		0
Total Canadian Installment Receivables	$	5,211	$	5,019	$	40	$	117
Total
Non-Impaired Installment receivables with no related allowance recorded		5,171		4,979		0		117
Impaired Installment receivables with a related allowance recorded		6,824		6,824		4,522		0
Total Installment Receivables	$	11,995	$	11,803	$	4,522	$	117

Installment receivables by class as of December 31, 2010 consist of the following (in thousands):

U.S.	Total Installment Receivables		Unpaid Principal   Balance		Related Allowance for Doubtful   Accounts		Interest Income  Recognized
Impaired Installment receivables with a related allowance recorded	$	7,153	$	7,153	$	4,822	$	0
Canada
Non-Impaired Installment receivables with no related allowance recorded		3,222		3,104		0		109
Impaired Installment receivables with a related allowance recorded		256		256		19		0
Total Canadian Installment Receivables	$	3,478	$	3,360	$	19	$	109
Total
Non-Impaired Installment receivables with no related allowance recorded		3,222		3,104		0		109
Impaired Installment receivables with a related allowance recorded		7,409		7,409		4,841		0
Total Installment Receivables	$	10,631	$	10,513	$	4,841	$	109

Installment receivables with a related allowance recorded as noted in the table above represent those installment receivables on a non-accrual basis in accordance with ASU 2010-20. As of June 30, 2011 and December 31, 2010, the Company had no U.S. installment receivables past due of 90 days or more for which the Company is still accruing interest. Individually, all U.S. installment receivables are assigned a specific allowance for doubtful accounts based on management's review when the Company does not expect to receive both the contractual principal and interest payments as specified in the loan agreement. However, while the full balance may be deemed to be impaired, the Company does historically collect a large percentage of the principal of its U.S. installment receivables.

The Company had an immaterial amount of Canadian installment receivables which were past due of 90 days or more as of June 30, 2011 and December 31, 2010, respectively, for which the Company is still accruing interest.

The aging of the Company's installment receivables was as follows (in thousands):

	June 30, 2011						December 31, 2010
	Total		U.S.		Canada		Total		U.S.		Canada
Current	$	5,111	$	0	$	5,111	$	3,097	$	0	$	3,097
0-30 Days Past Due		44		0		44		89		0		89
31-60 Days Past Due		18		0		8		31		0		31
61-90 Days Past Due		8		0		8		5		0		5
90+ Days Past Due		6,814		6,784		40		7,409		7,153		256
	$	11,995	$	6,784	$	5,211	$	10,631	$	7,153	$	3,478

XML



Net Earnings Per Common Share

6 Months Ended

Jun. 30, 2011

Net Earnings Per Common Share

Net Earnings Per Common Share

Net Earnings Per Common Share - The following table sets forth the computation of basic and diluted net earnings per common share for the periods indicated (amounts in thousands, except per share amounts).

	Three Months Ended          June 30,					Six Months Ended          June 30,
	2011		2010			2011		2010
	(In thousands, except per share data)
Basic
Average common shares outstanding		31,950		32,386			32,062		32,367
Net earnings (loss)	$	10,661	$	(611	)	$	18,115	$	2,495
Net earnings (loss) per common share	$	0.33	$	(0.02	)	$	0.56	$	.08
Diluted
Average common shares outstanding		31,950		32,386			32,062		32,367
Stock options and awards		534		0			442		124
Shares related to convertible debt		522		0			522		178
Average common shares assuming dilution		33,006		32,386			33,026		32,669
Net earnings (loss)	$	10,661	$	(611	)	$	18,115	$	2,495
Net earnings (loss) per common share	$	0.32	$	(0.02	)	$	0.55	$	0.08

At June 30, 2011, 1,387,621 and 1,955,770 shares were excluded from the average common shares assuming dilution for the three and six months ended June 30, 2011, respectively, as they were anti-dilutive since the majority of the anti-dilutive shares were granted at an exercise price of $41.87, which was higher than the average fair market value prices of $32.48 and $31.12, respectively. At June 30, 2010, 3,213,910 and 2,780,343 shares were excluded from the average common shares assuming dilution for the three and six months ended June 30, 2010 as they were anti-dilutive since the majority of the anti-dilutive shares were granted at an exercise price of $41.87, which was higher than the average fair market value prices of $24.59 and $25.76, respectively. The Company included the impact of 522,000 shares, for both the three and six months ended June 30, 2011, necessary to settle the conversion spread related to the Company's 4.125% Senior Subordinated Convertible Debentures due 2027 compared to zero and 302,000 shares for the three and six months ended June 30, 2010. This is attributable to the Company's average stock price during the first three and six months of both years being greater than the conversion price of $24.79, established under the indenture governing the convertible debentures. The dilutive impact of the convertible debt on diluted earnings per share is directly affected by changes in the Company's stock price and thus increased dilution in the future is possible if the Company's stock price increases.

XML



Business Segments

6 Months Ended

Jun. 30, 2011

Business Segments

Business Segments

Business Segments - The Company operates in five primary business segments: North America/Home Medical Equipment (NA/HME), Invacare Supply Group (ISG), Institutional Products Group (IPG), Europe and Asia/Pacific. The NA/HME segment sells each of three primary product lines, which includes: standard, rehab and respiratory products. Invacare Supply Group sells distributed product and the Institutional Products Group sells health care furnishings and accessory products. Europe and Asia/Pacific sell the same product lines as NA/HME and the Institutional Products Group. Each business segment sells to the home health care, retail and extended care markets.

The Company evaluates performance and allocates resources based on profit or loss from operations before income taxes for each reportable segment. The accounting policies of each segment are the same as those described in the summary of significant accounting policies for the Company's consolidated financial statements. Intersegment sales and transfers are based on the costs to manufacture plus a reasonable profit element. Therefore, intercompany profit or loss on intersegment sales and transfers is not considered in evaluating segment performance, except for Asia/Pacific due to its significant intercompany sales volume.

The information by segment is as follows (in thousands):

	Three Months Ended June  30,						Six Months Ended June  30,
	2011			2010			2011			2010
Revenues from external customers
North America / HME	$	198,732		$	190,089		$	384,345		$	365,075
Invacare Supply Group		75,737			72,826			149,783			142,544
Institutional Products Group		26,113			22,700			53,754			44,978
Europe		141,860			123,105			263,247			240,833
Asia/Pacific		23,970			22,108			43,781			39,638
Consolidated	$	466,412		$	430,828		$	894,910		$	833,068
Intersegment Revenues
North America / HME	$	22,334		$	22,395		$	43,201		$	43,343
Invacare Supply Group		24			19			40			32
Institutional Products Group		1,045			1,540			3,181			2,997
Europe		2,786			2,491			4,632			5,333
Asia/Pacific		9,997			8,548			17,943			15,784
Consolidated	$	36,186		$	34,993		$	68,997		$	67,489
Restructuring charges before income taxes
North America / HME	$	0		$	0		$	0		$	0
Invacare Supply Group		0			0			0			0
Institutional Products Group		0			0			0			0
Europe		431			0			431			0
Asia/Pacific		0			0			0			0
Consolidated	$	431		$	0		$	431		$	0
Earnings (loss) before income taxes
North America / HME	$	13,324		$	10,479		$	26,576		$	22,026
Invacare Supply Group		1,489			1,331			2,684			2,199
Institutional Products Group		3,764			3,331			7,885			5,138
Europe		9,480			9,293			14,440			13,827
Asia/Pacific		1,842			2,534			2,893			3,351
All Other *		(21,638	)		(24,554	)		(36,213	)		(38,821	)
Consolidated	$	8,261		$	2,414		$	18,265		$	7,720

* "All Other" consists of un-allocated corporate selling, general and administrative costs, which do not meet the quantitative criteria for determining reportable segments. In addition, "All Other" loss before income taxes includes loss on debt extinguishment including finance charges and associated fees.

XML



Condensed Consolidated Balance Sheets (USD $) In Thousands	Jun. 30, 2011	Dec. 31, 2010
ASSETS
Cash and cash equivalents	$ 38,162	$ 48,462
Trade receivables, net	268,753	252,004
Installment receivables, net	5,977	3,959
Inventories, net	188,812	174,375
Deferred income taxes	6,020	5,778
Other current assets	49,534	41,581
TOTAL CURRENT ASSETS	557,258	526,159
OTHER ASSETS	45,173	45,484
OTHER INTANGIBLES	72,271	70,911
PROPERTY AND EQUIPMENT, NET	134,037	130,763
GOODWILL	553,504	507,083
TOTAL ASSETS	1,362,243	1,280,400
LIABILITIES AND SHAREHOLDERS' EQUITY
Accounts payable	160,622	143,753
Accrued expenses	134,288	130,079
Accrued income taxes	1,405	8,502
Short-term debt and current maturities of long-term obligations	8,431	7,974
TOTAL CURRENT LIABILITIES	304,746	290,308
LONG-TERM DEBT	247,297	238,090
OTHER LONG-TERM OBLIGATIONS	107,255	99,591
SHAREHOLDERS' EQUITY
Preferred shares	0	0
Common shares	8,445	8,401
Additional paid-in-capital	221,821	231,685
Retained earnings	387,322	370,001
Accumulated other comprehensive earnings	171,905	112,631
Treasury shares	(86,820)	(70,579)
TOTAL SHAREHOLDERS' EQUITY	702,945	652,411
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	1,362,243	1,280,400
Common Class B [Member]
SHAREHOLDERS' EQUITY
Common shares	$ 272	$ 272